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 Angiogenesis, or the formation of new blood vessels, is an essential process in 
normal development as well as the pathological development of several diseases, 
including cancer. In an effort to identify novel angiogenesis inhibitors from existing 
drugs, the antifungal drug itraconazole was found to possess potent antiangiogenic 
activity that was unique among members of the azole antifungal class. However, despite 
promising early results in several phase 2 clinical trials for various types of cancer, its 
antiangiogenic mechanism of action remained unknown. We therefore sought to identify 
novel targets of itraconazole using a live cell photoaffinity labeling approach. Using a 
probe that retained the full cellular activity of itraconazole in endothelial cells, we 
identified two previously unknown binding partners of the drug: the mitochondrial 
Voltage-Dependent Anion Channel 1 (VDAC1) and the lysosomal protein Niemann-Pick 
type C 1 (NPC1). Inhibition of both targets leads to the inhibition of mTOR signaling 
through distinct pathways: VDAC1 is required for itraconazole-induced activation of the 
AMPK signaling pathway, an upstream effector of mTOR; and NPC1 inhibition causes a 
defect in cholesterol trafficking that also leads to mTOR inhibition. The simultaneous 
inhibition of these two pathways has a synergistic effect on mTOR inhibition, suggesting 
that the unique dual-targeted mechanism of itraconazole may give it an advantage over 
other anti-mTOR and antiangiogenic drugs.  
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Chapter 1: Introduction 
1.1: Approaches to Drug Discovery 
 
The discovery and development of new therapeutics to treat human diseases is 
arguably one of the most critical endeavors of modern society. It is also one of the most 
demanding of our society’s financial and human resources. From start to finish, the 
process of bringing one new drug to market now takes on the order of 10-15 years and 
upwards of $2.5 billion1, and is a major contributor to the unsustainable cost of healthcare 
in the United States and around the world. Thus, it is imperative that every measure be 
taken to make the entire process of drug development, from early preclinical research to 
approval, as efficient and effective as possible.  
 
Phenotypic vs. Target-based Drug Discovery 
 In the earliest recorded days of human medicine, illnesses were largely treated 
using plants and other substances found in nature that were observed to have an effect on 
the illness. The use of empirical observation to determine whether a given treatment has 
an effect on the phenotype, or observable traits, of a disease has given rise to thousands 
of medicines, many of which are still in use today. This so-called “phenotypic” approach 
to drug discovery is an unbiased, brute force method, but has the advantage that effective 
treatments can be identified and used without any prior knowledge about how the 
treatment actually works.  
 As medical science has progressed through the ages and our understanding of the 
basic biology underlying human diseases has reached the molecular level, the logic 
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behind drug discovery has largely shifted. We now understand that drugs fundamentally 
work by binding to, and altering the function of, one or more “target” molecules in the 
body, typically proteins. Thus, it was logical to infer that if we could use our 
understanding of disease pathology to identify a target protein that plays a key role in the 
disease pathology, we could design drugs with specific activity against that protein. This 
target-based approach to drug discovery has given rise to the modern era of precision 
medicine, and over the past 25 or so years the vast majority of drug discovery efforts in 
the pharmaceutical industry have been focused on targets. The advantage of this approach 
is that it is hypothesis-driven rather than observational, providing a rational, defined 
starting point for drug development studies. In addition, simplified systems such as 
purified proteins can be used to screen very large numbers of compounds for activity; 
alternatively, if the structure of the target is known, new inhibitors can be rationally 
designed to bind within a certain binding pocket that may disrupt the protein’s function. 
However, a major drawback to this approach is that there is no guarantee the drug 
candidate with the best activity against the chosen target will also have the most 
favorable activity in the context of the human body.  
Despite enormous advances in our understanding of and approach to drug 
development, the rate of new drug approval has stagnated in recent years, while research 
and development costs have skyrocketed. In trying to elucidate the reasons for this lack 
of productivity, recent retrospective studies have looked at the successes and failures of 
drug candidates and assessed which properties were associated with the drugs that were 
finally approved. Interestingly, it was shown that between 1999-2008, while most R&D 
efforts were focused on targeted therapeutics, a majority of the approved first-in-class 
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drugs were actually identified by phenotypic assays2. The authors of the study speculate 
that high attrition rates in clinical trials were often due to incorrect assumptions that 
activity against a chosen target would translate into efficacy against the disease with an 
acceptably large therapeutic window. As a result of this and other studies, there has been 
a resurgence of interest in phenotypic screening in recent years as a potentially more 
effective and unbiased approach to drug discovery3. In addition, the development of more 
sophisticated technologies for phenotypic screening has allowed for more relevant 
disease models, including cell and even some animal models, to be miniaturized to the 
point where compounds can be tested in much higher throughput.  
 
Drug Repurposing 
 Another important consideration in any drug discovery program is the selection of 
compounds from which to search for leads. Usually a large collection, or library, of 
chemical compounds is gathered and prepared in a format that can be used directly in the 
high-throughput assay of choice. Ideally, these compounds should have a wide range of 
different scaffolds, functional groups, and other physical properties to increase the 
likelihood of finding one with activity. The concentration of the chemicals is selected 
somewhat arbitrarily, at a relatively high level to ensure that compounds with moderate 
activity will show an effect, but not so high that too many hits are generated to follow up 
on. A balance must also be found in the number of compounds screened, as higher 
numbers are more likely to generate hits, but also use up larger amounts of resources and 
can potentially introduce greater experimental variability.  
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 The makeup of the chemical library used in a particular high-throughput screen 
should be chosen based on the desired goal of the project. In pharmaceutical industry, 
where the goal is usually to identify a novel structure with a good likelihood of having 
favorable pharmacokinetic properties, and where resources are not a large concern, it is 
common for libraries upwards of 1,000,000 compounds of widely varying properties to 
be screened. Another popular approach is to screen smaller libraries of chemical 
fragments, very small compounds of less than 500 daltons, from which moderately active 
pieces can later be patched together in different combinations to form an optimized 
ligand. In contrast to these approaches common in industry, more resource-limited 
programs such as academic labs or other non-profits do not typically handle such large 
numbers of compounds or chemical reactions. However, because the end goal of 
programs outside of industry is usually not to produce a commercializable product, but to 
find the most effective drug from the smallest number of compounds possible, there are 
different strategies that can be used very successfully in academia.  
 One powerful strategy to find effective drugs is to search the chemical space of 
drugs that are already known to be effective. This is the idea behind drug repurposing, or 
finding new uses for existing drugs. Because drugs that are already approved for clinical 
use are known to be effective against some condition and have tolerable safety and 
toxicity profiles, the likelihood of finding an active compound with good drug-like 
properties improves exponentially. If validated against a disease model in preclinical 
studies, repurposed drugs can potentially enter later stage clinical trials directly without 
the need for initial safety and toxicity studies, saving significant time and resources. In 
addition, once the patent on an approved drug has expired, generic forms of the drug can 
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be made available to patients very inexpensively, potentially reaching underprivileged 
populations for whom expensive new drugs are not always readily available.  
 In summary, of the many different approaches to drug discovery being used 
today, a strategy that combines high-throughput phenotypic screening and drug 
repurposing is arguably the most likely to yield effective new treatments that can be most 
rapidly translated to clinical use while also minimizing the resources required for their 
discovery. In the remainder of this chapter, I will describe the use of such a strategy to 
identify a clinically used antifungal drug, itraconazole, which was found through 
phenotypic screening to have antiangiogenic activity and has been repurposed as an 
anticancer drug.  
 
1.2: Angiogenesis and Cancer 
	
The term angiogenesis refers to the creation of new blood vessels from 
preexisting vasculature. This process is important during normal growth and 
development, but also in the pathology of several diseases, including cancer, macular 
degeneration, rheumatoid arthritis, pulmonary hypertension, and others4. In the case of 
malignant tumors, the rapidly proliferating, genetically altered cancer cells require a 
progressively increasing supply of nutrients to continue their uncontrolled growth. 
Tumors often promote the in-growth of new blood vessels for this purpose, by secreting 
proangiogenic growth factors including vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), and others5. For this reason, Dr. Judah Folkman 
postulated in the 1970’s that by inhibiting the growth of new blood vessels into the 
tumor, it might be possible to prevent the tumor from growing beyond a certain size, 
	 6	
rendering it effectively “dormant” and harmless to the host6. In addition, because the 
endothelial cells that line the blood vessels are genetically stable and do not proliferate as 
rapidly as cancer cells, targeting endothelial cells might lead to a decreased incidence of 
drug resistance7.  
Since this theory originated, a significant amount of effort has been dedicated to 
understanding, and designing inhibitors of, angiogenesis. Several clinical drugs have 
resulted from these studies, which have shown efficacy against various types of cancer 
alone or in combination with chemotherapy8. Based on the work of researchers such as 
Folkman and others on the molecular mechanisms underlying angiogenesis, the majority 
of currently used antiangiogenic drugs were developed using a targeted approach to 
inhibit the VEGF signaling axis. Monoclonal antibodies against VEGF (e.g. 
Bevacizumab) and its receptor VEGFR (e.g. Ramucirumab) are being used or tested in a 
variety of different types of cancers, including colorectal, lung, and gastric cancers9,10. 
Another anti-VEGF strategy is the use of soluble “decoy” receptors (e.g. Aflibercept), 
which bind VEGF in the circulation and prevent it from reaching the VEGFR11. Small 
molecule tyrosine kinase inhibitors (e.g. sorafenib, sunitinib, regorafenib), which inhibit 
the kinase activity of VEGFR, PDGFR, FGFR, and other proangiogenic receptors, are 
also being used to treat cancer.  
Although these treatments have proven efficacious in certain cancers, they are 
also generally prone to acquired resistance or insensitivity. As with most other targeted 
cancer therapies, genetically unstable cancer cells are often able to find ways to overcome 
the treatment, by developing mutations in the target proteins themselves that prevent the 
drugs from binding, and/or reducing their dependence on the target through some other 
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compensatory mechanism. For example, in the case of anti-VEGF therapies, other growth 
factors such as FGF, PDGF, etc. can stimulate angiogenesis and therefore, once VEGF 
becomes ineffective, the tumor cells can upregulate production of another factor12. These 
transformations often mean that such therapeutics are only able to provide transient 
benefits to the patient and do not necessarily translate to increases in overall survival.  
In light of these challenges, it is likely that monotargeted therapies will not be the 
best solution for angiogenesis inhibition going forward, and the use of mechanistically 
distinct drugs, either sequentially or in combination, will be necessary for sustained 
responses in these patients. In addition, relying only on our existing knowledge of the 
mechanisms underlying angiogenesis to design new inhibitors is problematic, as it limits 
the number of potential targets to a tiny fraction of all druggable space. Logically, it is 
highly likely that of the 20,000+ genes in the human genome, several regulators of 
angiogenesis have not yet been identified that could potentially be effective drug targets. 
Unbiased, phenotypic drug screening is therefore more likely to yield mechanistically 
distinct drugs that can expand the portfolio of antiangiogenic treatments.  
 
1.3: Repurposing Itraconazole as an Antiangiogenic/Anticancer Drug 
	
With the goal of identifying novel angiogenesis inhibitors from the existing drug 
space, a library of clinically used, mostly FDA-approved drugs was assembled and 
screened for inhibitors of primary Human Umbilical Vein Endothelial Cell (HUVEC) 
proliferation as a proxy for angiogenesis13. A promising hit to emerge from this screen 
was the antifungal drug itraconazole, with an IC50 of 150-200 nM for inhibition of 
HUVEC proliferation. Because the plasma concentration of itraconazole during a 
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standard course of treatment can reach as high as 3.2 μM, these concentrations are likely 
to be attainable during normal dosing regimens. The proliferation inhibition was shown 
to be selective for endothelial cells (both HUVEC and Bovine Aortic Endothelial Cells, 
BAEC) over other cell types, including Human Foreskin Fibroblasts (HFF), HeLa, and 
Jurkat T cells, suggesting a specific antiangiogenic effect13. Itraconazole’s activity was 
further validated in an in vivo matrigel angiogenesis assay, where a growth factor-
secreting gel is implanted into mice and the number of blood vessels that grow into the 
gel is quantified. In addition, itraconazole was shown to inhibit the growth of prostate and 
lung cancer xenografts in mice, demonstrating its anticancer potential13,14.  
Shortly after the discovery and validation of itraconazole’s antiangiogenic 
activity, another screen of the same clinical drug library identified itraconazole as a novel 
inhibitor of the Hedgehog signaling pathway15. The Hedgehog pathway is most well 
studied in the context of organismal development, but has also been implicated in adult 
human diseases including several types of cancer. Hyperactivation of the pathway is 
observed in a large majority of basal cell carcinomas (BCC) and at least a third of 
medulloblastoma cases16. Thus, there has been considerable interest in the development 
of Hedgehog pathway inhibitors. 
The Hedgehog signaling pathway is initiated by binding of the Hedgehog ligand 
to its receptor, Patched. Through mechanisms that are not completely understood, 
Patched then releases its inhibitory hold on Smoothened, allowing Smoothened to 
translocate to the primary cilium and triggering a cascade of events leading to activation 
of the Gli transcription factor that controls Hedgehog target gene expression. Using the 
Gli-responsive luciferase reporter cell line Shh-Light 2, itraconazole was shown to inhibit 
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pathway activation with an IC50 of ~800 nM. This inhibition was shown to occur at the 
level of Smoothened, preventing its translocation to the primary cilium15. Itraconazole 
also inhibited Gli1 expression in mice, as well as growth of medulloblastoma xenografts 
and endogenous basal cell carcinomas, demonstrating antihedgehog and anticancer 
activity in vivo.  
 
Clinical Studies of Itraconazole in Cancer 
Itraconazole has been in clinical use for decades, and its pharmacokinetic 
properties and safety and toxicity profiles are thoroughly documented. Because of this, it 
has been able to move rapidly into clinical trials as an investigational anticancer drug. 
Several trials have been initiated in different types of cancer, including prostate, breast, 
lung, and basal cell carcinomas (Table 1.1). The results of three of these trials have been 
published to date. A phase 2 trial in castration-resistant metastatic prostate cancer 
(CRPC) where patients were given either 200 or 600 mg/day itraconazole demonstrated a 
median progression-free survival (PFS) of 35.9 weeks in the high-dose arm, which is 
considered comparable to other investigational treatments in this population, whereas the 
low-dose arm (200 mg/day) had a median PFS of 11.9 weeks17. Additionally, Hedgehog 
signaling, as measured by Gli1 expression in skin punch biopsies, and circulating tumor 
cell counts were also suppressed in a majority of the patients in the study. A phase 2 trial 
in non-small cell lung cancer (NSCLC) in which patients were given pemetrexed with or 
without itraconazole (200 mg/day) demonstrated an increase in 3-month PFS (67% vs. 
27%), median PFS (5.5 months vs. 2.8 months) and median overall survival (32 months 
vs. 8 months) in the itraconazole arm18. A phase 2 trial in basal cell carcinoma (BCC) 
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showed a decrease in tumor cell proliferation (45%), Hedgehog signaling (65%) and 
tumor area (24%) after itraconazole treatment19. In addition, prior to these three trials 
specifically assessing itraconazole’s anticancer activity, another study had investigated 
itraconazole as an antifungal prophylactic in patients with neutropenic leukemia receiving 
daunorubicin and found that the disease-free survival rate of acute lymphoblastic 
leukemia (ALL) was higher in the itraconazole-treated arm, which was attributed to 
reversal of multidrug resistance20. Several case reports have also been published showing 
apparent effects of itraconazole treatment in prostate cancer, pancreatic cancer, cutaneous 




Table 1.1: Ongoing and recently completed clinical trials investigating itraconazole as an anticancer agent in the US 
(information compiled from http://www.clinicaltrials.gov)
Title Condition Sponsor/Collaborators 
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) 
Combined With Itraconazole In Men With Castration-Resistant 
Prostate Cancer (CRPC) 
Prostate Cancer 
Emmanuel Antonarakis, MD|Millennium 
Pharmaceuticals, Inc.|Johns Hopkins 
University 
A Phase II Study of Itraconazole in Biochemical Relapse Prostate Cancer University of California, San Francisco 
Study of Itraconazole in Castrate-resistant Prostate Cancer 
(CRPC) Post-chemotherapy Prostate Cancer Stanford University 
A Two-dose Level Clinical Trial of Itraconazole in Patients 
With Metastatic Prostate Cancer Who Have Had Disease 
Progression While on Hormonal Therapy 
Prostate Cancer Johns Hopkins University|Memorial Sloan Kettering Cancer Center 
Neoadjuvant Itraconazole in Non-small Cell Lung Cancer Non-small Cell Lung Cancer 
University of Texas Southwestern Medical 
Center|United States Department of Defense 
A Randomized Phase II Study of SUBATM-itraconazole in 
Patients With Untreated Squamous NSCLC. 
Non-small Cell Lung 
Cancer 
Sidney Kimmel Comprehensive Cancer 
Center 
A Randomized Phase II Study of Itraconazole and Pemetrexed 
in Patients With Previously Treated Non-Squamous Non-Small 
Cell Lung Cancer 
Non Small Cell Lung 
Cancer 
Sidney Kimmel Comprehensive Cancer 
Center 
A Pilot Trial of Itraconazole Pharmacokinetics in Patients With 
Metastatic Breast Cancer Breast Cancer Indiana University 
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in 
Subjects With Basal Cell Carcinoma Nevus Syndrome 
(BCCNS) 
Basal Cell Carcinoma in 
Basal Cell Nevus 
Syndrome 
HedgePath Pharmaceuticals, Inc. 
Topical Itraconazole in the Treatment of Basal Cell Carcinoma Basal Cell Carcinoma Johns Hopkins University 
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in 
Patients w/ Basal Cell Carcinomas Basal Cell Carcinoma Stanford University 
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Because itraconazole has been in clinical use for many years, retrospective studies 
have also been performed to evaluate the outcomes of patients with various cancers who 
were treated with itraconazole. These studies have shown a potential benefit of 
itraconazole treatment in ovarian clear cell carcinoma25, refractory ovarian cancer26, 
recurrent triple-negative breast cancer27, metastatic pancreatic cancer28, and metastatic 
biliary tract cancer29, providing a rationale for further studies with itraconazole in these 
cancer types. However, it is worth noting that in all of the above clinical studies, there 
can be no conclusive determination that the observed effects of itraconazole are due to 
angiogenesis inhibition, Hedgehog inhibition, MDR reversal, or some other undescribed 
activity. 
Although itraconazole is well tolerated and side effects are generally mild, it has 
been shown to cause hepatotoxicity in a small subset of patients due to its interaction 
with CYP450 enzymes. Participants in the above phase 2 trials had their liver function 
monitored throughout the course of their treatment and no liver toxicities were reported, 
although the duration of these trials was relatively short. Depending on the prognosis of 
the patient, the low risk of liver toxicity may be outweighed by the potential benefit if life 
expectancy is short otherwise. The commercial formulation of itraconazole contains a 
mixture of the 4 cis-stereoisomers in a 1:1:1:1 ratio, and a recent study found that the 
antiangiogenic activity of these 4 stereoisomers did not track with their hepatotoxicity, 
suggesting the two effects can be separated30. Stereochemistry at the 2 and 4 positions 
had a greater influence on antiangiogenic activity while the 2’ position affected 
hepatotoxicity (Figure 1.1). One stereoisomer designated IT-C (2S,4R,2’S) had both 
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better antiangiogenic potency and less hepatotoxicity than the commercial mixture, 





Figure 1.1: Itraconazole structure and stereocenters30. Itraconazole has three 
stereocenters, designated 2, 4, and 2’, giving rise to 8 possible stereoisomers. The 
commercial itraconazole formulation is a mixture of equal amounts of the 4 cis-
stereoisomers, where the triazole and ethoxyphenyl-containing substituents are on the 
same side of the dioxolane ring (i.e. 2S4R or 2R4S).   
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Mechanistic Studies 
 Like other azole antifungal drugs, itraconazole exerts its activity through binding 
to the fungal P450 enzyme lanosterol 14-α-demethylase (14DM; CYP51). This enzyme 
catalyzes the first step in the conversion of lanosterol to ergosterol, an important 
structural sterol required for maintenance of membrane integrity in fungal cells. The 
azole drugs bind in the active site of the enzyme and one of the basic azole nitrogen 
atoms (N3 for imidazole drugs and N4 for triazoles) coordinates the iron of the heme 
group, leading to reversible enzyme inhibition31. 14DM is also expressed in mammalian 
cells, where it is analogously involved in the cholesterol biosynthetic pathway; however, 
it has been shown that the azole drugs, including itraconazole, have a significantly lower 
affinity for the human enzyme than the fungal enzyme32,33.  
 Although itraconazole’s antifungal mechanism of action is well established, 
several pieces of evidence suggested that the antiangiogenic activity is likely not 
mediated by 14DM inhibition. First, other azole antifungals that have been shown to have 
greater potency against human 14DM have significantly lower potency for HUVEC 
inhibition13. Second, a similar lack of correlation was observed when all eight individual 
stereoisomers of itraconazole were synthesized and tested in HUVEC and yeast, strongly 
suggesting the two activities are likely to be mediated by different targets34. Finally, an 
analog of itraconazole that lacks the triazole ring was synthesized and shown to retain 
significant antiproliferative activity in HUVEC (Figure 1.2)35. These results suggest that 
there may be one or more other molecular targets of itraconazole that contribute to its 

















Figure 1.2: Structure and activity of triazole-deleted itraconazole. (A) Structure of 
triazole-deleted itraconazole (TD-itra) and (B) its antiproliferative activity in HUVEC, as 





In attempting to elucidate the mechanism of action of itraconazole, several key 
phenotypes were observed that possibly contribute to its activity in endothelial cells. 
Itraconazole was shown to induce cell cycle arrest in the G1 phase, which was associated 
with decreased expression of the cell cycle regulatory proteins Cyclin A, Cyclin E and 
p21, and increased expression of p2736. Similar effects had been previously reported for 
the natural product rapamycin, which inhibits the mechanistic target of rapamycin 
(mTOR) signaling pathway and also has antiangiogenic activity37,38. Similarly, 
itraconazole was shown to inhibit mTOR signaling in HUVEC, as measured by 
phosphorylation of the mTOR kinase substrates ribosomal protein s6 kinase (S6K) and 
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1). Because the IC50 for 
mTOR inhibition in HUVEC was the same as for proliferation inhibition (between 100-
300 nM after 24 hours treatment), it was thought that the antiangiogenic activity of 
itraconazole was likely mediated by this mTOR inhibitory activity.  
 It was also shown that itraconazole induced accumulation of cholesterol into 
perinuclear vesicles that colocalized with the late endosomal-lysosomal resident protein 
LAMP1, preventing its trafficking to the plasma membrane and other organelle 
membranes36. This cholesterol trafficking defect is characteristic of cells from patients 
with Niemann-Pick type C (NPC) disease, where a deficiency in one of two lysosomal 
proteins, NPC1 and NPC2, prevents cholesterol from being properly transported out of 
the lysosome to the rest of the cell (referred to as NPC phenotype). It was shown that 
adding exogenous cholesterol delivered in complex with the carrier molecule β-
cyclodextrin to itraconazole-treated cells partially reversed both the proliferation 
inhibition and mTOR inhibition. In addition, shRNA knockdown of NPC1 or NPC2 led 
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to inhibition of mTOR signaling in HUVEC, and other small molecules known to induce 
NPC phenotype (U18666a and imipramine) had a similar effect, suggesting a connection 
between cholesterol trafficking and mTOR signaling in endothelial cells.  
 Another interesting effect of itraconazole in HUVEC was discovered while 
monitoring levels of VEGFR2 protein, an important mediator of VEGF-induced 
angiogenesis. It was found that treatment with itraconazole caused a change in the 
electrophoretic mobility of the protein, leading to a downward shift on SDS-PAGE. This 
gel shift was eventually attributed to hypoglycosylation of the receptor39. Proper 
glycosylation of VEGFR2 is required for the correct localization of the receptor at the 
cell surface and thus its availability for binding and activation by its ligand; accordingly, 
inhibition of glycosylation leads to intracellular accumulation and failure to stimulate the 
proangiogenic signaling pathway. This effect was specific to itraconazole over other 
azole antifungals tested, suggesting that it was not due to inhibition of 14DM, and it was 
also not a consequence of mTOR inhibition or cholesterol trafficking as other 
mTOR/cholesterol trafficking inhibitors failed to induce the same defect in VEGFR2 
glycosylation. Likewise, other glycosylation inhibitors failed to inhibit mTOR or 
cholesterol trafficking, suggesting that the two phenotypes were likely parallel 
consequences of itraconazole treatment. Similar to the mTOR/NPC phenotype, however, 
the glycosylation defect was also partially reversed by adding cholesterol/cyclodextrin 
complex to itraconazole-treated cells. In addition to VEGFR2, effects of itraconazole on 
the glycosylation of VEGFR1, EGFR, Fcγ and CD14 receptors have been reported, 
suggesting a global defect in N-linked glycosylation39–41.  
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 In order to determine whether the effects of itraconazole observed in endothelial 
cells were related to the Hedgehog inhibition, a structure-activity relationship (SAR) 
study was performed using a number of itraconazole analogs with modifications to the 
isobutyl side-chain42. Analogs were assayed for HUVEC proliferation and VEGFR2 
glycosylation, as well as proliferation and Gli1 transcription in a medulloblastoma 
culture. Overall, a lack of correlation between antiproliferative potency in the two 
cultures was observed, and the apparent structural determinants for VEGFR2 
glycosylation inhibition (≥4 carbon side-chain length with branching at the α or β 
carbon) differed from those for Gli1 transcription inhibition (≥3 carbon length, no 
branching at β carbon or polar modifications), suggesting that the antiangiogenic and 
anti-hedgehog effects of itraconazole are likely mediated by different targets. In light of 
these results, I have focused on itraconazole’s antiangiogenic effects in this thesis work, 
although it is worth noting that both aspects of itraconazole’s mechanism may play a role 
in its anticancer activity.  
1.4: Target Identification 
	
 Although a significant amount of work has been performed in trying to 
understand itraconazole’s molecular mechanism of action (MMOA), the direct target(s) 
mediating its antiangiogenic activity had not been found. Target identification is an 
important step not just in understanding how a particular drug works at a molecular level, 
but also illuminating the underlying biological processes governing a disease and 
potentially identifying improved treatment strategies.  
Approaches to identifying the targets of small molecules can be broadly grouped 
into two categories: top-down, where the cellular phenotype of the drug is used to narrow 
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down its potential targets based on their known functions, or bottom-up, where the target 
is identified directly by chemical or genetic means (Figure 1.3)43. The studies described 
above, where the effects of itraconazole were observed in cells, fall into the category of a 
top-down approach. These studies provided clues to the cellular changes that might 
underlie the ultimate phenotype of angiogenesis inhibition, which helps narrow down the 
list of potential targets to proteins involved in those cellular processes affected by the 
drug (e.g. cholesterol trafficking, mTOR signaling, glycosylation, etc.). However, a major 
disadvantage of the top-down approach is that it relies on what is already known about 
these processes, and does not account for the possibility that the real target is a protein 
whose function has not been characterized or has not been previously described to be 







Figure 1.3: Two approaches to target identification. The top-down approach begins 
with observation of a phenotype and narrows down the possible targets based on their 
known functions. The bottom-up approach starts with direct identification of the target 
protein and then up to connect that target with the observed phenotype. Figure from Titov 
and Liu, 201243.  
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The bottom-up approach circumvents this problem by identifying the target 
directly in an unbiased manner. This can be accomplished by genetic means; for example, 
by screening an shRNA library for knockdown cell lines that confer resistance or 
hypersensitivity to the drug, or by isolating drug-resistant cell lines and using deep 
sequencing to determine which genes contain mutations that confer resistance. These 
types of experiments can identify key proteins or pathways related to the activity of the 
drug, but do not necessarily prove direct binding to the identified protein. Chemical 
approaches, on the other hand, typically involve the use of a chemical probe to bind to the 
target protein directly and allow its isolation and identification. Designing a probe that 
retains its ability to bind to the target protein requires the use of structure-activity 
relationship (SAR) studies to identify a position on the molecule that can be modified 
without significant loss of activity. It also requires that the probe be able to bind its target 
with high enough affinity that it can be isolated from other cellular proteins (i.e. affinity 
purified), and that these proteins retain their ability to bind the small molecule outside of 
their native cellular environment. This requirement can be problematic for certain targets; 
for example, integral membrane proteins often require a specific lipid environment to 
maintain their active conformation, and may become aggregated or improperly oriented 
for ligand binding once cells are lysed. One way to circumvent this issue is to design a 
chemical probe containing a crosslinking moiety that can covalently attach to the target 
protein and thus allow it to be isolated without regard to affinity. A common crosslinking 
strategy for such probes is to use a photolabile group, such as a diazirine or 
benzophenone, which becomes activated upon irradiation with UV light and covalently 
inserts into whatever protein is nearest.  
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The goal of this thesis work has been to identify the direct target(s) of 
itraconazole that mediate its antiangiogenic activity, with the aim of understanding its 
MMOA as well as uncovering new potential targets for the future development of 
mechanistically distinct antiangiogenic drugs. To accomplish this, I used a cell-active 
photoaffinity probe of itraconazole to identify its binding proteins in live cells, and 
performed target validation studies to identify these proteins’ connection to known 
phenotypes of itraconazole in endothelial cells. In the course of this work, I identified a 
previously unknown connection between the outer mitochondrial membrane channel 
VDAC1 and the mTOR signaling pathway in endothelial cells (Chapter 2), and 
uncovered a novel dual-targeted mechanism of small-molecule-induced mTOR inhibition 
(Chapter 3). The relevance of these studies and future directions will be discussed in 
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Chapter 2: VDAC1 as a Direct Target of Itraconazole and 
Mediator of AMPK Activation in Endothelial Cells1 
2.1: Abstract 
 
Itraconazole, a clinically used antifungal drug, was found to possess potent 
antiangiogenic and anticancer activity that is unique among the azole antifungals. 
Previous mechanistic studies have shown that itraconazole inhibits the mechanistic target 
of rapamycin (mTOR) signaling pathway, which is known to be a critical regulator of 
endothelial cell function and angiogenesis. However, the molecular target of itraconazole 
that mediates this activity has remained unknown. In this chapter, I describe the 
identification of the major binding protein of itraconazole in endothelial cells as the 
mitochondrial protein voltage-dependent anion channel 1 (VDAC1), which regulates 
mitochondrial metabolism by controlling the passage of ions and small metabolites 
through the outer mitochondrial membrane. VDAC1 knockdown profoundly inhibits 
mTOR activity and cell proliferation in primary human umbilical vein endothelial cells 
(HUVEC), uncovering a previously unknown connection between VDAC1 and mTOR. 
Inhibition of VDAC1 by itraconazole disrupts mitochondrial metabolism, leading to an 
increase in the cellular AMP:ATP ratio and activation of the AMP-activated protein 
kinase (AMPK), an upstream regulator of mTOR. VDAC1-knockout cells are resistant to 
																																																								
1 The following chapter is adapted from Head, S. A. et al. Antifungal drug itraconazole 
targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc. 
Natl. Acad. Sci. U.S.A. 112, E7276–7285 (2015). 
	
	 29	
AMPK activation and mTOR inhibition by itraconazole, demonstrating that VDAC1 is 
the mediator of this activity. In addition, another known VDAC-targeting compound, 
erastin, also activates AMPK and inhibits mTOR and proliferation in HUVEC. VDAC1 
thus represents a novel upstream regulator of mTOR signaling in endothelial cells and a 





14DM, lanosterol 14-α-demethylase; 2DG, 2-deoxyglucose; ABKAR, AMPK and BRSK 
kinase activity reporter; ACC, acetyl coA carboxylase; AMPK, AMP-activated protein 
kinase; AXP, adenine nucleotides (AMP/ADP/ATP); CPT2, carnitine 
palmitoyltransferase 2; DMSO, dimethyl sulfoxide; FRET, fluorescence resonance 
energy transfer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HUVEC, human 
umbilical vein endothelial cells; IC50, 50% inhibitory concentration; Itra, itraconazole; 
JHDL, Johns Hopkins Drug Library; MEF, mouse embryonic fibroblast; mEH, 
microsomal epoxide hydrolase; MS, mass spectroscopy; mTOR, mechanistic target of 
rapamycin; NPC, Niemann-Pick type C; Raptor, regulatory associated protein of TOR; 
S6K, ribosomal protein S6 kinase; TD-itra, triazole deleted itraconazole; TSC2, tuberous 
sclerosis complex 2; VDAC, voltage-dependent anion channel; VEGF, vascular 







Angiogenesis, or the formation of new blood vessels from preexisting vasculature, 
is a critical process both in normal development and in the pathogenesis of a myriad of 
diseases. In particular, it has long been recognized that angiogenesis is required for tumor 
growth and metastasis, and growing tumors can promote angiogenesis by secreting pro-
angiogenic factors, such as VEGF, bFGF, EGF, and others1,2. These pro-angiogenic 
factors stimulate the proliferation, migration, and differentiation of the endothelial cells 
that make up the inner layer of all blood vessels, causing them to form new vessels that 
grow toward the source of these factors. This process, termed tumor angiogenesis, allows 
the tumor to keep up with an increasing demand for oxygen and nutrients as it grows, 
eliminate accumulating waste products, and shed cancerous cells into circulation leading 
to metastasis. Without angiogenesis, a tumor cannot grow larger than about 1-2 mm in 
diameter, the largest size at which nutrients can permeate by diffusion alone, and is thus 
rendered essentially harmless to the host3. Inhibition of angiogenesis is emerging as a 
useful strategy for treating cancer. The discovery and development of angiogenesis 
inhibitors as novel therapeutics for cancer has culminated in the FDA approval of a few 
antiangiogenic drugs.  Bevacizumab (Avastin), a monoclonal antibody targeting VEGF, 
gained FDA approval for the treatment of metastatic colorectal cancer4,5.  Pegaptanib 
(Macugen), a polynucleotide-based aptamer targeting VEGF6, has also been approved by 
the FDA for the treatment of age-dependent macular degeneration.  More recently, 
several kinase inhibitors, including sorafenib, sunitinib, pazopanib and everolimus, that 
have a major, albeit non-specific, effect on angiogenesis have also entered the clinic7.   
Drug discovery and development is a time-consuming and costly process. The 
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discovery and development of anti-angiogenic drugs is no exception. To accelerate the 
process, our lab began a new initiative to collect known drugs and assemble them into 
what is now known as the Johns Hopkins Drug Library (JHDL). Screening of JHDL 
using an endothelial cell proliferation assay led to the discovery of a number of hits. 
Among the novel and most interesting hits is the antifungal drug itraconazole8. 
Itraconazole potently inhibits endothelial cell proliferation with an IC50 value (ca. 200 
nM) that is significantly below its peak plasma levels (> 2 µM)9, suggesting that it is 
likely to have antiangiogenic activity under existing drug administration regimens. It also 
displays high cell type selectivity, being most potent against primary human endothelial 
cells in comparison to human foreskin fibroblasts and most human cancer cell lines. 
Moreover, it is over 30-fold more potent than other members of the azole family of 
antifungal drugs, including ketoconazole and terconazole8.  
Itraconazole was originally developed as an antifungal drug, and has been used 
clinically for over 30 years with a well-established safety record. Upon validation of its 
antiangiogenic and antitumor activity in a number of models both in vitro and in 
vivo8,10,11, it entered multiple phase 2 clinical trials for treating cancer. To date, the pilot 
trials in non-small cell lung cancer, prostate cancer, and basal cell carcinoma have been 
completed; itraconazole has been shown to increase the progression-free and overall 
survivals of patients taking the drug12–14. Thus, itraconazole has great potential in 
becoming a new drug to treat cancer and other angiogenesis-dependent diseases such as 
macular degeneration and diabetic retinopathy.  
Despite these promising clinical results, the mechanism of angiogenesis inhibition 
by itraconazole has remained largely unknown. Like other azole-containing antifungal 
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drugs, itraconazole exerts its antifungal activity by inhibiting the CYP450 enzyme 
lanosterol 14-α demethylase (14DM), which is required for synthesis of the lipid 
ergosterol that maintains cell wall integrity in these organisms. However, the potency of 
itraconazole against human 14DM has been shown to be greatly reduced as compared to 
the fungal enzyme15,16. Moreover, itraconazole is unique among this class of antifungal 
drugs in its antiangiogenic activity, including those which are more potent inhibitors of 
human 14DM8. Taken together, these lines of evidence strongly suggest that 14DM 
inhibition cannot explain the antiangiogenic activity of itraconazole.  
In an attempt to identify cellular pathways affected by itraconazole, we found that 
the mechanistic target of rapamycin (mTOR) signaling pathway, which regulates cell 
proliferation and is known to be required for angiogenesis, is potently inhibited by 
itraconazole at concentrations similar to those required for proliferation inhibition17. This 
mTOR inhibitory activity is also more potent in endothelial cells, both primary and 
immortalized, as compared with other common cell lines such as HEK-293T and HeLa. 
We found that inhibition of mTOR was mediated, only in part, by inhibition of 
cholesterol trafficking through the endolysosome, leaving unanswered the question of 
what is the direct molecular target of itraconazole.  
In this chapter, I describe the use of a photoaffinity probe of itraconazole to 
isolate and identify its binding proteins from live endothelial cells. Importantly, the probe 
retained full activity in endothelial cells, indicating that it binds to the same target 
proteins as itraconazole itself. Using a combination of affinity pull-down and mass 
spectrometry, VDAC1 was identified as a primary binding protein of itraconazole. I 
demonstrate that itraconazole not only directly binds to VDAC1, but also interferes with 
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its primary cellular function of regulating mitochondrial metabolism, causing a drop in 
cellular energy levels that triggers the energy-sensing protein AMP-activated protein 
kinase (AMPK). Subsequently, AMPK downregulates mTOR activity through direct 
phosphorylation of the regulatory-associated protein of mTOR (raptor), ultimately 
leading to inhibition of endothelial cell proliferation.  
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2.3: Materials and Methods 
	
Reagents and antibodies 
 Itraconazole was purchased from TCI Chemicals (I0732; Philadelphia, PA). 
Erastin (E7781) and Ionomycin (I9657) were from Sigma-Aldrich (St Louis, MO). 2DG 
was from LKT laboratories (D1859; St. Paul, MN). STO-609 was from Enzo Life 
Sciences (BML-EI389; Farmingdale, NY). Alexa Fluor 647-azide (A10277), TCEP 
(20490) and High Capacity Streptavidin Agarose beads (20359) were from Life 
Technologies (Grand Island, NY). Biotin-azide was from Click Chemistry Tools (AZ104-
100; Scottsdale, AZ). TBTA was from Anaspec (63360-50; Fremont, CA). Copper 
Sulfate was from LabChem Inc (LC13440-1; Pittsburgh, PA). A769662 was from Abcam 
(ab120335; Cambridge, MA). Compound C was from Calbiochem (171261; San Diego, 
California). Antibodies against AMPKα (2532), phospho-AMPKα Thr172 (2535), ACC 
(3676), phospho-ACC Ser79 (3661), phospho-p70 S6K Thr389 (9205), raptor (2280), 
phospho-raptor Ser792 (2083), TSC2 (3990), phospho-TSC2 Ser1387 (5584) and 
AMPKγ2 (2536) were from Cell Signaling Technologies (Danvers, MA). Antibodies 
against p70 S6K (sc-8418), GAPDH (sc-20357), Tubulin (sc-5286), VDAC1 (sc-58649), 
and Tom 40 (sc-11414) were from Santa Cruz Biotechnologies (Santa Cruz, CA). The 
antibody against 14DM was from Proteintech (13431-1-AP; Chicago, IL). The antibody 
against AMPKγ1 was from Abcam (ab32382; Cambridge, MA). DOPC and DOPE were 
from Avanti Polar Lipids, Inc. (Alabaster, AL).	 
Synthesis of itraconazole probe and triazole-deleted itraconazole 
The itraconazole photoaffinity probe was synthesized by Dr. Wei Shi, and the 
triazole-deleted itraconazole was synthesized by Dr. Kalyan Kumar, both former Liu lab 
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members. The details of these syntheses have been published18.  
Cell culture 
 Primary HUVEC pooled from 4 donors (Lonza) were cultured in complete EGM-
2 (Lonza) and subcultured every 2 days at a density of 1:4, or 3 days at 1:8, and discarded 
after passage 8. HEK 293T, HeLa, and A549 were cultured in low glucose DMEM 
(Gibco; Gaithersburg, MD) supplemented with 10% filtered FBS (Gibco) and 1% 
penicillin/streptomycin (Gibco). VDAC1 wild-type and knockout MEFs were generated 
as previously reported19 and cultured in high glucose DMEM supplemented with 10% 
filtered FBS and 1% penicillin/streptomycin. All cells were cultured at 37°C with 5% 
CO2. 
Photoaffinity labeling  
Photoaffinity labeling was performed according to the protocol of MacKinnon 
and Taunton, with modifications20. Cells were seeded into 6-cm dishes in 4 mL of culture 
media to achieve near complete confluence after settling overnight. Cells were pre-treated 
with competitor (as noted in text) or an equal volume of DMSO vehicle for 30 min, 
before addition of 200 nM probe or DMSO, with a final DMSO concentration in all 
samples of 0.5%. After a 1-h incubation with the probe, the dishes were placed on ice. 
Cells were washed 1x with 5 mL ice-cold PBS (pH 7.4) to remove excess probe, and re-
covered with 4 mL ice-cold PBS before being placed 3 cm under a Spectroline FC100 
365 nm UV lamp (Westbury, NY) for 3 min on top of an ice pack to minimize heating 
from the lamp. After irradiation, the PBS was aspirated completely and 200 µL of ice-
cold PBS (pH 8.5) containing protease inhibitor cocktail (Roche Life Science, 
Indianapolis, IN) was added to the dish. Cells were removed from the dish by scraping 
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and transferred to an Eppendorf tube kept on ice, and SDS was added to a final 
concentration of 0.4%. The cell suspension was then sonicated for 10 pulses using a 
Branson Sonifier 250 (Danbury, CT) set to output 1, duty cycle 30%, and incubated on 
ice for 1 min before a second round of 10 pulses. After sonication, samples were 
incubated at 95°C for 5 min to complete cell lysis and denature all of the proteins. The 
concentration of total proteins in the lysate was then measured by the detergent 
compatible (Dc) protein assay kit (BioRad, Hercules, CA), and normalized to 2.5 mg/mL 
(or in the case of HUVEC, the highest concentration possible). For the click reaction with 
fluor-azide, 40 µL of lysate was removed and transferred to a new tube, and 0.2 µL Alexa 
Fluor 647 azide (1 mM stock solution in DMSO), 0.58 µL TCEP (100 mM stock with 4 
equivalents NaOH added), 3.38 µL TBTA (1.7 mM stock in 4:1 t-butanol:DMSO) were 
added sequentially and vortexed to mix. CuSO4-5H2O (1.14 µL, 50 mM stock in water) 
was then added to start the reaction. The samples were briefly vortexed again and 
incubated at room temperature for 30 min in the dark. Aliquots of 50 µL 2X SDS sample 
buffer were then added and samples subjected to SDS-PAGE before being scanned on a 
Typhoon FLA 9500 gel scanner (GE Healthcare Life Sciences; Piscataway Township, 
NJ) using a red excitation laser. For the click reaction with biotin-azide, the maximum 
amount of lysate obtained after protein normalization was used, and 1.38 µL biotin-azide 
(10 mM stock in DMSO), 5.5 µL TCEP, 32.5 µL TBTA, and 11 µL CuSO4-5H2O were 
added per 500 µL of lysate. The samples were vortexed and incubated at room 
temperature for 30 min, after which time 4 volumes of cooled acetone (-20 °C) were 
added to the lysate to precipitate the proteins, and samples were incubated overnight at -
80 °C. The precipitated proteins were pelleted by centrifugation at 17,000 x g for 15 min 
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at 4 °C. The supernatant was aspirated completely. The pellet was then completely 
resuspended by sonication in 150 µL PBS containing 1% SDS, after which 600 µL of 
PBS was added to dilute the SDS to 0.2%. The lysates were then added to 30-40 µL high 
capacity streptavidin agarose beads pre-washed 2x in PBS, and incubated with rotation at 
4 °C for 1 h. The beads were collected by centrifugation at 800 x g at room temperature 
for 3 min, and washed 3x with wash buffer (400 mM NaCl, 50 mM Tris, 0.2% SDS, pH 
7.4) for 5 min each with rotation at room temperature. After the final wash, beads were 
boiled in 40 µL 2X SDS sample buffer, and subjected to SDS-PAGE before silver 
staining or transfer to nitrocellulose membranes for Western blot.  
Target identification by MS 
Silver stained SDS-PAGE bands were cut out and destained with the SilverQuest 
kit following the manufacture's protocol (Thermofisher Inc., Waltham, MA). Each gel 
band was then cut into small pieces and placed in a 1.5 ml Eppendorf tube. The gel pieces 
were washed with water for 1 hour and then with 25 mM ammonium bicarbonate solution 
in 50% acetonitrile for 10 min. The sample was dehydrated by 100% acetonitrile and 
dried in a SpeedVac (Thermofisher Inc.). Sequencing-grade trypsin (Promega, Madison, 
WI) was reconstituted in 50 mM ammonium bicarbonate solution and added to the 
sample for overnight digestion at 37 °C. The tryptic peptides were extracted from the gel 
pieces with sequential wash in 50% acetonitrile and 100% acetonitrile, respectively. The 
solution from both extractions were pooled and dried by SpeedVac. The sample was then 
desalted with a C18 Ziptip following the manufacturer's protocol (Millipore Inc., 
Billerica, MA). The tryptic peptides were dissolved in HPLC buffer A (0.1% formic acid 
in water) and then manually injected into the LCMS system with Eksigent 1D plus nano 
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HPLC (AB Sciex Inc., Framingham, MA) and LTQ Orbitrap Velos mass spectrometer 
(Thermofisher Inc.). The peptides were analyzed on an in-house packed capillary C18 
column (75 µm ID and 10 cm in length, 3 µm C18 beads (Dr. Maisch Inc., Ammerbuch, 
Germany)) using a linear gradient of 5-30% HPLC buffer B (0.1% formic acid in 
acetonitrile) for 60 minutes at 200 nL/min. The data were analyzed by Mascot v2.1 
(Matrix Science, London, UK) for protein identification with a default p-value cutoff of 
0.05. Identified peptides were manually evaluated to remove false positive 
identifications. 
Western blot 
 Cells (100,000/well in 2 mL media) were seeded in 6-well plates 24 h before drug 
treatment. Drugs were then added to each well from 200x DMSO stock solutions (final 
DMSO concentration of 0.5%), and incubated for the indicated times. Plates were then 
placed on ice and washed once with ice-cold PBS before addition of 2X Laemmli sample 
buffer directly to the cells. Lysates were collected after 10 min and incubated for 5 min at 
95°C before being subjected to SDS-PAGE. Proteins were then transferred to 
nitrocellulose membranes (Bio-Rad) and stained with ponceau to confirm the quality of 
protein transfer and equal loading of samples. Membranes were then incubated in 5% w/v 
blotto (Santa Cruz Biotechnologies) dissolved in TBS containing 0.05% Tween-20 
(TBST) for 1 h at room temperature before overnight incubation with primary antibodies 
at 4 °C. Membranes were washed 3 times for 5 min each with TBST, and then incubated 
with HRP-conjugated secondary antibodies (GE healthcare) diluted in 5% blotto/TBST 
for 1 h at room temperature. Membranes were then washed another 3 times for 5 min 
with TBST before the immune complexes were detected with Chemiluminescent ECL 
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substrate (Millipore) on a Kodak Image Station (440CF). Band intensity was quantified 
using ImageJ.  
VDAC1/2/3-V5 expression plasmids 
 VDAC1 and VDAC2 expression plasmids in pLX304 backbone and VDAC3 
entry clone in pENTR223 backbone were provided by The ORFeome Collaboration21, 
(PlasmID clone IDs HsCD00420021, HsCD00421586, and HsCD00370222; PMIDs 
21706014 and 154893350). Storage and distribution provided by the PlasmID Repository 
at Harvard Medical School and funded in part by NCI Cancer Center Support Grant 
#NIH 5 P30 CA06516. The VDAC3 expression plasmid was obtained by Gateway 
recombination of the entry clone into the pEF-DEST51 destination vector (Invitrogen, 
Carlsbad, CA).  
Thymidine incorporation assay 
 HUVEC or MEFs were seeded in 96-well plates (Costar, Corning, NY) at a 
density of 2000/well and allowed to attach overnight. Drugs were serially diluted in 
DMSO at 200x final concentrations (0.5% DMSO), then diluted in media before addition 
to the cells. Cells were incubated with drugs for 24 hours before addition of 1µCi per 
well of [3H]-labeled thymidine (American Radiolabeled Chemicals, St. Louis, MO) for a 
further 6 hours. Cells were then harvested onto glass fiber filters (PerkinElmer, Norwalk, 
CT) using a Mach III M Harvester 96 (Tomtec Inc., Hamden, CT). Filters were dried 
overnight before being sealed in sample bags with 4 mL of Betaplate Scint scintillation 
fluid (PerkinElmer), and then scintillation was counted using a 1450 Microbeta apparatus 
(PerkinElmer). The counts-per-minute (CPM) of drug-treated cells were normalized to 
control cells treated with DMSO alone. Drug dose-response curves and IC50 values were 
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generated using GraphPad Prism 5 software.  
shRNA plasmids 
 Short hairpins were designed targeting two non-overlapping sequences within the 
coding region of human VDAC1, mEH, and CPT2. Complimentary sets of page-purified 
oligonucleotides were ordered from IDT technologies, and the sequences are shown in 
Table 2.1. Forward and reverse primers were annealed and ligated into the lentiviral 
vector pSicoR digested with HpaI/XhoI, before being confirmed by sequencing.  
Table 2.1: shRNA primers 






































Adenine nucleotide extraction 
 AXP were extracted by the hot methanol method described by Shryock et. al24. 
HUVEC were plated in 10-cm dishes at a density of 700k/dish and allowed to settle 
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overnight. Cells were treated with DMSO or drugs as indicated, with a final DMSO 
concentration of 0.5%. After drug treatment, the cells were washed twice with 10 mL of 
PBS, before the addition of 1 mL of extractant (80% methanol with 0.5 mM EGTA) 
preheated to 70°C. Cells were scraped immediately from the plate, transferred to an ice-
cold microcentrifuge tube, and centrifuged for 5 min at 1000 x g at 4°C to pellet 
precipitated matter. The supernatants were then transferred to a new ice-cold tube, dried 
by Speedvac, and stored at -20°C until immediately before analysis. The extracts were 
then reconstituted in 100 µL 50% acetonitrile, and centrifuged at 14,000 x g for 5 min at 
4°C before supernatants were taken for analysis. 
AMP/ATP analysis by LC-MS/MS 
 AMP and ATP analysis were performed on an Agilent 6490 triple quadrupole LC-
MS/MS system with iFunnel and Jet-Stream® technology (AgilentTechnologies, Santa 
Clara, CA) equipped with an Agilent 1260 infinity pump and autosampler. 
Chromatographic separation was performed on a Diamond Hydride column (150mm x 
2.1 mm i.d., 4µm particle size, Microsolv, Eatontown, NJ). The LC parameters were as 
follows: autosampler temperature, 4°C; injection volume, 4 µl; column temperature, 
35°C; and flow rate, 0.4 ml/min. The solvents and optimized gradient conditions for LC 
were: Solvent A, water with 5mM ammonium acetate, pH=7.2; Solvent B, 90% 
acetonitrile with 10mM ammonium acetate, pH=6.5; elution gradient: 0 min 95% B; 15–
20 min 25% B; post-run time for equilibration, 5 min in 95% B. MS was operated in 
positive-ion electrospray mode (unit resolution) with all analytes monitored by SRM. 
AMP was monitored by the transition of 348à136 (collision energy: 23ev). ADP was 
monitored by the transition of 428à136 (collision energy: 30ev). ATP was monitored by 
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the transition of 508à136 (collision energy: 35ev). Compound identity was confirmed 
by comparison to the retention times of pure standards. The optimized operating ESI 
conditions were: gas temperature 230°C (nitrogen); gas flow 15 L/min; nebulizer 
pressure 40 psi; sheath gas temperature 350°C and sheath gas flow 12 L/min. Capillary 
voltages were optimized to 4000V in positive mode with nozzle voltages of 2000 V. The 
iFunnel parameters were: 130V for high pressure RF and 80V for low pressure RF. All 
data processing was performed with Mass Hunter Quantitative Analysis software package. 
 
Lentivirus production 
 Lentivirus was produced using the second generation system developed by the 
laboratory of Didier Trono25. HEK293T cells were plated 2.0 x 107 in a 15-cm dish and 
allowed to settle overnight. Each dish was co-transfected with 9 µg lentiviral expression 
vector, 6 µg of the packaging vector psPAX2, and 3 µg of the envelope vector pMD2.G, 
using 45 µL of Lipofectamine 2000 (Life Technologies). The culture media was 
harvested 48 hours later and virus particles were concentrated by ultracentrifugation at 
25,000 rpm (~100,000 x g) for 2.5 hours using a Beckman Optima LE-80k 
ultracentrifuge (Beckman Coulter, Fullerton, CA) and a Beckman SW-28 rotor, before 
being resuspended in EGM-2 media and aliquoted into 4 cryotubes stored at -80°C. One 
tube of virus was used to transduce 100,000 HUVEC, and experiments were performed 
2-5 days later.  
FRET imaging 
The generation of ABKAR was previously described26,27 and the construct was 
verified by sequencing. HUVEC were nucleofected with ABKAR using a nucleofection 
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kit from Lonza (VAPB-1002; Walkersville, MD) according to the manufacturer’s 
protocol, and plated into 35-mm glass bottom dishes to 50-70% confluence. Cells were 
imaged 24 h after nucleofection. Itraconazole and 2-deoxyglucose were added directly to 
the culture media as indicated. Images were acquired using a Zeiss Axiovert 200M 
inverted fluorescence microscope (Carl Zeiss, Thornwood, NY) with a 40x/1.3 NA oil-
immersion objective lens and a cooled charge-coupled device camera (Roper Scientific, 
Trenton, NJ) controlled by Metafluor 7.7 software (Molecular Devices, Sunnyvale, CA). 
Dual cyan/yellow emission ratio imaging was performed using a 420DF20 excitation 
filter, a 450DRLP dichroic mirror, and two emission filters (475DF40 for CFP and 
535DF25 for YFP). Filter sets were alternated using a Lambda 10–2 filter changer (Sutter 
Instruments, Novato, CA). Exposure time was set to 500 ms, and images were taken 
every 30-180 s. Raw fluorescence images were corrected by subtracting the background 
fluorescence intensity of a cell-free region from the emission intensities of biosensor 
expressing cells. Emission ratios (yellow/cyan or cyan/yellow) were then calculated at 
each time point. All time-courses were normalized by dividing the emission ratio at each 
time point by the basal value immediately preceding drug addition.  
Fatty acid oxidation assay 
300,000 HUVEC were seed in T25 flasks (~80% confluent) in 5 mL fresh EGM-
2, along with 2 control flasks containing media only. 14C oleic acid (1 µL/sample) was 
added to pre-warmed media (0.5 mL/sample) containing 1% BSA + 100 µM carnitine 
and incubated in a 37°C water bath for 1 h. During this hour, cells were pretreated with 
drug or DMSO. The oleic acid mixture was then added to each flask (0.5 mL/sample), the 
flasks were sealed with a rubber stopper containing a piece of folded filter paper to catch 
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the 14CO2 produced, and returned to the culture incubator for 6 h. The reaction was 
quenched by injection of 200 µL 1M perchloric acid through the stopper into the media, 
and 200 µL 1M NaOH was injected onto the filter paper. The flasks were then incubated 
at 60°C for 1 h, after which time the stoppers were removed from the flasks in a fume 
hood and the filter paper was moved to a vial for scintillation counting.  
Mitochondrial swelling assay 
 Mitochondria were isolated from livers of male Sprauge-Dawley rats according to 
a previously published protocol28. Mitochondria were diluted to a final protein 
concentration of 250 µg/mL into H-buffer (70 mM sucrose, 210 mM mannitol, 0.1 mM 
EGTA, 5.0 mM HEPES, pH 7.5) plus 5 mM phosphate buffer, pH 7.4, in a 3 mL volume 
in a glass test tube pre-washed in H-buffer. Diluted mitochondria were then gently 
vortexed during the addition of 3 µL DMSO or 1000x drug stock (0.1% DMSO final 
concentration) to ensure adequate mixing of the drug and mitochondria. The samples 
were transferred to a quartz cuvette containing a mini stir bar and placed into a 
CHEMUSB4-UV-VIS spectrophotometer (Ocean Optics, Dunedin, FL) on top of a stir 
plate, and baseline absorbance at 400 nm was recorded for 5 min before the addition of 
400 µL 1 mM CaCl2 diluted in H-buffer. Traces of absorbance vs. time were plotted in 
Microsoft Excel and the maximum rate of swelling during a 10-second interval shortly 
after calcium addition was calculated using the linear fitting function.   
VDAC purification and planar lipid bilayer electrophysiology 
VDAC channels were purified from rat liver mitochondria29 and channel 
experiments were conducted as previously described30. All experiments were performed 
in the laboratory of Drs. Sergei Bezrukov and Tatiana Rostovtseva at the National 
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Institutes of Health using custom equipment. Purified channels were reconstituted in a 
planar bilayer made up of the lipids DOPC and DOPE in a 1:1 mixture. Membranes were 
formed across a hole of 2 divisions in diameter in the partition separating cis and trans 
compartments, and hexadecane was used to coat the hole prior to membrane formation. 
Multichannel experiments were performed using a triangular wave of voltage between +/- 
60 mV and with a frequency of 5 mHz. For single channel recordings, a constant voltage 
was applied either in 5 sec pulses or continuously until channel closure was achieved. 
Channel recordings were filtered with 500 Hz Bessel filter. Single channel experiments in 
the presence of tubulin were performed at voltages between 15-30 mV and pH 7.4, and 
single channel experiments in the absence of tubulin were performed at 50-60 mV and 
pH 6. Itraconazole was added to both sides of the membrane from DMSO stock solutions 
in final concentrations between 500 nM-10 µM as indicated. The final concentration of 






Design of a photoaffinity probe of itraconazole that retains full cellular activity 
In order to identify molecular target(s) of itraconazole, we turned to a live-cell 
photoaffinity labeling approach, which allows capture of drug-binding proteins in their 
native environment and unbiased target identification by mass spectrometry. For this 
approach to be successful, a probe must be designed that can bind to the same target 
proteins and induce the same effects as the parent drug with a similar potency. Our 
previous studies on all eight individual stereoisomers of itraconazole revealed that the 
stereochemistry in the sec-butyl side chain is least important for the growth inhibition of 
HUVEC31. Therefore, we speculated that the alkyl group attached to the triazolone ring 
might be a suitable position for derivatization to make a chemical probe for target 
identification.  Further elaborated structure–activity relationship (SAR) studies proved 
this hypothesis32.  It was found that a relatively large alkyl substituent with sufficient 
lipophilicity could replace the sec-butyl group without a significant loss of activity in 
HUVEC. Thus, we designed a photoaffinity probe of itraconazole by replacing the 
isobutyl sidechain with a bifunctional “tail” containing a photosensitive diazirine moiety, 
which covalently crosslinks the probe to its binding protein(s), and a terminal alkyne for 
attachment of an affinity tag through click chemistry (Figure 2.1). The probe was 
confirmed to induce all of the same previously reported effects in HUVEC as 
itraconazole, including mTOR inhibition, NPC phenotype, VEGFR2 hypoglycosylation, 
and proliferation inhibition, with a similar potency as itraconazole (Figure 2.2), giving 
confidence that the probe is likely acting upon the same molecular target as itraconazole 
itself.   
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Figure 2.1: Itraconazole and photoaffinity probe structure. The modification to the 

































Figure 2.2: The photoaffinity probe is active in HUVEC. The probe induces the same 
effects in HUVEC as itraconazole, including: A) mTOR inhibition, as measured by 
phosphorylation of S6K; B) proliferation inhibition, as measured by 3H-thymidine 
incorporation; C) NPC phenotype, observed by filipin staining; and D) VEGFR2 
hypoglycosylation, as measured by mobility shift on SDS-PAGE. The experiments 
shown in panels C and D were performed by Dr. Benjamin Nacev (Ita-43 = probe). 
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Identification of three itraconazole-binding proteins by photoaffinity labeling 
Initial photoaffinity labeling experiments were performed in 293T cells, due to the 
difficulty of obtaining large amounts of protein from HUVEC. The workflow of the 
photoaffinity labeling experiment is depicted in Figure 2.3. Live cells in culture were 
treated with 200 nM probe for 1 hour, with or without pretreatment with 5 µM 
itraconazole for 30 minutes to compete with the binding of the probe to specific binding 
proteins. The cells were then placed under a UV lamp for 3 minutes to activate the 
photolabile diazirine and covalently crosslink the probe to its binding proteins, after 
which the cells were lysed and proteins denatured. The denatured lysates were then 
reacted with fluor-azide in the presence of copper, which reacts with the terminal 
acetylene of the probe to covalently attach the fluorophore via click chemistry. The 
proteins were then resolved on an SDS-PAGE gel, which was scanned on a fluorescence 















Figure 2.3: Schematic depicting the photoaffinity labeling experiment workflow. 
Live cells are treated with the probe, which binds to its target protein in the cell. After 
UV irradiation, the diazirine is crosslinked to the target protein. Click reaction with an 
azide-linked affinity tag (i.e. biotin or fluorophore) then covalently attaches the tag to the 
probe for subsequent detection or isolation.  In a parallel competition experiment, the 
cells are pretreated with an excess of unmodified parent compound (grey circle), which 
binds to the target protein and prevents the binding of the probe. Thus, specific binding 
proteins will show a decreased signal in the competition sample. Cartoons were created 
by Dr. Wei Shi.  
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By comparing the background bands present in the DMSO control sample to the 
probe-treated sample, we observed that there were 3 proteins clearly photolabeled by the 
probe, of approximately 35, 50, and 70 kDa (Figure 2.4). The labeling of these proteins 
was also reduced in the competition sample containing excess itraconazole, indicating 
that these were specific binding proteins of itraconazole. To isolate and identify these 
itraconazole-binding proteins, the photocrosslinking experiment was repeated using 
biotin-azide instead of fluor-azide, and the biotinylated proteins were isolated on 
streptavidin-agarose beads before being resolved by SDS-PAGE. The isolated proteins 
were then visualized by silver staining, and the silver-stained protein bands were cut out 
of the gel and subjected to in-gel trypsin digestion and mass-spectrometry analysis. A 
slice of gel from the same region of the DMSO control lane was analyzed in parallel to 
subtract any non-specific proteins present in the samples (Tables 2.2-2.7). The highest 
scoring proteins for the 35, 50, and 70 kDa bands present only in the probe sample were 
Voltage Dependent Anion Channel 1 (VDAC1), microsomal Epoxide Hydrolase 



















Figure 2.4: Live cell photolabeling experiment in 293T cells. The itraconazole 
photoaffinity probe labels 3 predominant bands, as detected by fluorescence gel scanning 
after click reaction with fluor-azide. The intensity of the bands is decreased in the 




Table 2.2: MS results from DMSO sample (35 kDa) 
rank prot_acc prot_desc (Tax_Id=9606 Gene_Symbol) prot_score prot_mass 
1 IPI00291006 MDH2 Malate dehydrogenase, mitochondrial 752 35481 
2 IPI00219217 LDHB L-lactate dehydrogenase B chain 700 36615 
3 IPI00022434 ALB Putative uncharacterized protein ALB 227 71658 
4 IPI00027462 S100A9 Protein S100-A9 226 13234 
5 IPI00013933 DSP Isoform DPI of Desmoplakin 223 331569 
6 IPI00027547 DCD Dermcidin 218 11277 
7 IPI00398625 HRNR Hornerin 178 282228 
8 IPI00008530 RPLP0 60S acidic ribosomal protein P0 167 34252 
9 IPI00396378 HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 159 37407 
10 IPI00789324 JUP cDNA FLJ60424, highly similar to Junction plakoglobin 156 62577 
11 IPI00021700 PCNA Proliferating cell nuclear antigen 156 28750 
12 IPI00219221 LGALS7;LGALS7B Galectin-7 148 15066 
13 IPI00397801 FLG2 Filaggrin-2 148 247928 
14 IPI00025753 DSG1 Desmoglein-1 138 113644 
15 IPI00217966 LDHA Isoform 1 of L-lactate dehydrogenase A chain 127 36665 
16 IPI00007047 S100A8 Protein S100-A8 123 10828 
17 IPI00025447 EEF1A1 Elongation factor 1-alpha 122 47839 
18 IPI00021439 ACTB Actin, cytoplasmic 1 117 41710 
19 IPI00219018 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 86 36030 
20 IPI00790298 - 20 kDa protein 86 19534 
21 IPI00915869 MDH1 Malate dehydrogenase 80 23024 
22 IPI00005969 CAPZA1 F-actin-capping protein subunit alpha-1 78 32902 
23 IPI00654755 HBB Hemoglobin subunit beta 76 15988 
24 IPI00014587 CLTA Isoform Brain of Clathrin light chain A 76 27060 
25 IPI00019038 LYZ Lysozyme C 75 16526 
26 IPI00022974 PIP Prolactin-inducible protein 69 16562 
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27 IPI00032325 CSTA Cystatin-A 67 11000 
28 IPI00166729 AZGP1 alpha-2-glycoprotein 1, zinc precursor 65 34237 
29 IPI00329332 STX12 Syntaxin-12 63 31622 
30 IPI00216099 DSC1 Isoform 1A of Desmocollin-1 60 99924 
31 IPI00554711 JUP Junction plakoglobin 57 81693 
32 IPI00013885 CASP14 Caspase-14 54 27662 
33 IPI00219806 S100A7 Protein S100-A7 51 11464 
34 IPI00387020 MYOZ2 Myozenin-2 51 29879 
35 IPI00215911 APEX1 DNA-(apurinic or apyrimidinic site) lyase 50 35532 




Table 2.3: MS results from Probe sample (35 kDa) 
rank prot_acc prot_desc (Tax_Id=9606 Gene_Symbol) prot_score prot_mass 
1 IPI00013933 DSP Isoform DPI of Desmoplakin 847 331569 
2 IPI00216308 VDAC1 Voltage-dependent anion-selective channel protein 1 749 30754 
3 IPI00027462 S100A9 Protein S100-A9 673 13234 
4 IPI00745872 ALB Isoform 1 of Serum albumin 649 69321 
5 IPI00219217 LDHB L-lactate dehydrogenase B chain 560 36615 
6 IPI00291006 MDH2 Malate dehydrogenase, mitochondrial 495 35481 
7 IPI00789324 JUP cDNA FLJ60424, highly similar to Junction plakoglobin 398 62577 
8 IPI00025753 DSG1 Desmoglein-1 341 113644 
9 IPI00218918 ANXA1 Annexin A1 300 38690 
10 IPI00397801 FLG2 Filaggrin-2 272 247928 
11 IPI00398625 HRNR Hornerin 262 282228 
12 IPI00554711 JUP Junction plakoglobin 236 81693 
13 IPI00021439 ACTB Actin, cytoplasmic 1 222 41710 
14 IPI00219806 S100A7 Protein S100-A7 209 11464 
15 IPI00011229 CTSD Cathepsin D 192 44524 
16 IPI00007047 S100A8 Protein S100-A8 190 10828 
17 IPI00019038 LYZ Lysozyme C 189 16526 
18 IPI00179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 169 17953 
19 IPI00060800 ZG16B Zymogen granule protein 16 homolog B 169 22725 
20 IPI00032325 CSTA Cystatin-A 167 11000 
21 IPI00790298 - 20 kDa protein 163 19534 
22 IPI00022204 SERPINB3 Isoform 1 of Serpin B3 155 44537 
23 IPI00219221 LGALS7;LGALS7B Galectin-7 152 15066 
24 IPI00027547 DCD Dermcidin 145 11277 
25 IPI00418169 ANXA2 Isoform 2 of Annexin A2 131 40386 
26 IPI00300376 TGM3 Protein-glutamine gamma-glutamyltransferase E 128 76584 
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27 IPI00219018 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 124 36030 
28 IPI00216298 TXN Thioredoxin 112 11730 
29 IPI00007797 FABP5;FABP5L2;FABP5L7;FABP5L9 Fatty acid-binding protein, epidermal 107 15155 
30 IPI00947285 SBSN suprabasin isoform 1 precursor 106 60505 
31 IPI00008530 RPLP0 60S acidic ribosomal protein P0 104 34252 
32 IPI00216099 DSC1 Isoform 1A of Desmocollin-1 103 99924 
33 IPI00154742 
IGL@;IGLV1-40;IGLC1;IGLV3-21;IGLC3;LOC100293277;IGLV2-
14;LOC100293440;IGLV1 100 24777 
34 IPI00021536 CALML5 Calmodulin-like protein 5 97 15883 
35 IPI00022974 PIP Prolactin-inducible protein 96 16562 
36 IPI00166729 AZGP1 alpha-2-glycoprotein 1, zinc precursor 95 34237 
37 IPI00010303 SERPINB4 Serpin B4 93 44825 
38 IPI00217966 LDHA Isoform 1 of L-lactate dehydrogenase A chain 91 36665 
39 IPI00025447 EEF1A1 Elongation factor 1-alpha 89 47839 
40 IPI00396378 HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 88 37407 
41 IPI00024145 VDAC2 Isoform 2 of Voltage-dependent anion-selective channel protein 2 87 30393 
42 IPI00013885 CASP14 Caspase-14 85 27662 
43 IPI00013877 HNRNPH3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein H3 82 36903 
44 IPI00103242 POF1B Isoform 1 of Protein POF1B 80 68653 
45 IPI00015614 PRSS3 Isoform A of Trypsin-3 76 32508 
46 IPI00384938 LOC100290320;IGHG1;IGHV4-31;LOC100294459 Putative uncharacterized protein D 73 52819 
47 IPI00031564 GGCT Isoform 1 of Gamma-glutamylcyclotransferase 70 20994 
48 IPI00910602 NEFH Isoform 1 of Neurofilament heavy polypeptide 67 112411 
49 IPI00005969 CAPZA1 F-actin-capping protein subunit alpha-1 63 32902 
50 IPI00033583 SERPINB12 Serpin B12 58 46247 
51 IPI00019502 MYH9 Isoform 1 of Myosin-9 58 226392 
52 IPI00152881 SHROOM3 shroom family member 3 protein 56 216724 
53 IPI00003348 GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 55 37307 
54 IPI00291560 ARG1 Isoform 1 of Arginase-1 52 34713 
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Table 2.4: MS results from DMSO sample (50 kDa) 
rank prot_acc prot_desc (Tax_Id=9606 Gene_Symbol) prot_score prot_mass 
1 IPI00025491 SNORA67;EIF4A1 Eukaryotic initiation factor 4A-I 740 46125 
2 IPI00013933 DSP Isoform DPI of Desmoplakin 665 331569 
3 IPI00396485 EEF1A1 Elongation factor 1-alpha 1 572 50109 
4 IPI00000875 TUT1;EEF1G cDNA FLJ56389, highly similar to Elongation factor 1-gamma 526 56114 
5 IPI00025753 DSG1 Desmoglein-1 463 113644 
6 IPI00003881 HNRNPF Heterogeneous nuclear ribonucleoprotein F 414 45643 
7 IPI00789324 JUP cDNA FLJ60424, highly similar to Junction plakoglobin 344 62577 
8 IPI00009328 EIF4A3 Eukaryotic initiation factor 4A-III 328 46841 
9 IPI00554711 JUP Junction plakoglobin 297 81693 
10 IPI00031461 GDI2 cDNA FLJ60299, highly similar to Rab GDP dissociation inhibitor beta 293 51121 
11 IPI00299000 PA2G4 Proliferation-associated protein 2G4 281 43759 
12 IPI00021435 PSMC2 26S protease regulatory subunit 7 235 48603 
13 IPI00027547 DCD Dermcidin 228 11277 
14 IPI00398625 HRNR Hornerin 206 282228 
15 IPI00219525 PGD 6-phosphogluconate dehydrogenase, decarboxylating 174 53106 
16 IPI00021439 ACTB Actin, cytoplasmic 1 174 41710 
17 IPI00219575 BLMH Bleomycin hydrolase 165 52528 
18 IPI00009032 SSB Lupus La protein 160 46808 
19 IPI00001661 RCC1 regulator of chromosome condensation 1 isoform a 157 48115 
20 IPI00013847 UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial 150 52612 
21 IPI00397801 FLG2 Filaggrin-2 140 247928 
22 IPI00015614 PRSS3 Isoform A of Trypsin-3 123 32508 
23 IPI00032140 SERPINH1 Serpin H1 120 46411 
24 IPI00300376 TGM3 Protein-glutamine gamma-glutamyltransferase E 87 76584 
25 IPI00027230 HSP90B1 Endoplasmin 85 92411 
26 IPI00012835 CTBP1 C-terminal-binding protein 1 83 47505 
27 IPI00013885 CASP14 Caspase-14 83 27662 
28 IPI00013068 EIF3E Eukaryotic translation initiation factor 3 subunit E 77 52187 
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29 IPI00026256 FLG Filaggrin 76 434922 
30 IPI00790298 - 20 kDa protein 75 19534 
31 IPI00022434 ALB Putative uncharacterized protein ALB 75 71658 
32 IPI00071509 PKP1 Isoform 2 of Plakophilin-1 56 82808 
33 IPI00103242 POF1B Isoform 1 of Protein POF1B 55 68653 
34 IPI00550746 NUDC Nuclear migration protein nudC 50 38219 
35 IPI00010154 GDI1 Rab GDP dissociation inhibitor alpha 50 50550 
36 IPI00334627 ANXA2P2 Putative annexin A2-like protein 50 38635 
37 IPI00387020 MYOZ2 Myozenin-2 50 29879 
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Table 2.5: MS results from Probe sample (50 kDa) 
rank prot_acc prot_desc (Tax_Id=9606 Gene_Symbol) prot_score prot_mass 
1 IPI00013933 DSP Isoform DPI of Desmoplakin 929 331569 
2 IPI00025753 DSG1 Desmoglein-1 738 113644 
3 IPI00009896 EPHX1 Epoxide hydrolase 1 708 52915 
4 IPI00000875 TUT1;EEF1G cDNA FLJ56389, highly similar to Elongation factor 1-gamma 579 56114 
5 IPI00396485 EEF1A1 Elongation factor 1-alpha 1 447 50109 
6 IPI00397801 FLG2 Filaggrin-2 439 247928 
7 IPI00789324 JUP cDNA FLJ60424, highly similar to Junction plakoglobin 355 62577 
8 IPI00300376 TGM3 Protein-glutamine gamma-glutamyltransferase E 303 76584 
9 IPI00013885 CASP14 Caspase-14 303 27662 
10 IPI00398625 HRNR Hornerin 276 282228 
11 IPI00027547 DCD Dermcidin 273 11277 
12 IPI00334627 ANXA2P2 Putative annexin A2-like protein 263 38635 
13 IPI00025491 SNORA67;EIF4A1 Eukaryotic initiation factor 4A-I 262 46125 
14 IPI00291560 ARG1 Isoform 1 of Arginase-1 254 34713 
15 IPI00216099 DSC1 Isoform 1A of Desmocollin-1 240 99924 
16 IPI00219575 BLMH Bleomycin hydrolase 240 52528 
17 IPI00554711 JUP Junction plakoglobin 211 81693 
18 IPI00003881 HNRNPF Heterogeneous nuclear ribonucleoprotein F 206 45643 
19 IPI00021536 CALML5 Calmodulin-like protein 5 189 15883 
20 IPI00790298 - 20 kDa protein 184 19534 
21 IPI00465248 ENO1 Isoform alpha-enolase of Alpha-enolase 166 47139 
22 IPI00465436 CAT Catalase 155 59719 
23 IPI00247167 NCCRP1 Non-specific cytotoxic cell receptor protein 1 homolog 155 30828 
24 IPI00021439 ACTB Actin, cytoplasmic 1 151 41710 
25 IPI00216298 TXN Thioredoxin 146 11730 
26 IPI00027462 S100A9 Protein S100-A9 135 13234 
27 IPI00219018 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 132 36030 
28 IPI00022974 PIP Prolactin-inducible protein 128 16562 
	 62	
29 IPI00219525 PGD 6-phosphogluconate dehydrogenase, decarboxylating 127 53106 
30 IPI00305622 TGM1 Protein-glutamine gamma-glutamyltransferase K 118 89730 
31 IPI00022434 ALB Putative uncharacterized protein ALB 115 71658 
32 IPI00033583 SERPINB12 Serpin B12 112 46247 
33 IPI00166729 AZGP1 alpha-2-glycoprotein 1, zinc precursor 107 34237 
34 IPI00179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 104 17953 
35 IPI00013847 UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial 104 52612 
36 IPI00299000 PA2G4 Proliferation-associated protein 2G4 100 43759 
37 IPI00386809 CDSN Corneodesmosin 91 51463 
38 IPI00009328 EIF4A3 Eukaryotic initiation factor 4A-III 88 46841 
39 IPI00103242 POF1B Isoform 1 of Protein POF1B 86 68653 
40 IPI00419215 A2ML1 Alpha-2-macroglobulin-like protein 1 77 161001 
41 IPI00021435 PSMC2 26S protease regulatory subunit 7 76 48603 
42 IPI00156689 VAT1 Synaptic vesicle membrane protein VAT-1 homolog 74 41893 
43 IPI00219806 S100A7 Protein S100-A7 74 11464 
44 IPI00654755 HBB Hemoglobin subunit beta 68 15988 
45 IPI00654788 FLG Profilaggrin (Fragment) 68 133528 
46 IPI00032325 CSTA Cystatin-A 67 11000 
47 IPI00219221 LGALS7;LGALS7B Galectin-7 66 15066 
48 IPI00007047 S100A8 Protein S100-A8 59 10828 
49 IPI00031461 GDI2 cDNA FLJ60299, highly similar to Rab GDP dissociation inhibitor beta 58 51121 
50 IPI00023078 C1orf68 Skin-specific protein 32 53 26219 




Table 2.6: MS results from DMSO sample (70 kDa) 
rank prot_acc prot_desc (Tax_Id=9606 Gene_Symbol) prot_score prot_mass 
1 IPI00008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 477 63417 
2 IPI00304925 HSPA1A;HSPA1B Heat shock 70 kDa protein 1A/1B 436 70009 
3 IPI00004860 RARS Isoform Complexed of Arginyl-tRNA synthetase, cytoplasmic 300 75331 
4 IPI00017617 DDX5 Probable ATP-dependent RNA helicase DDX5 291 69105 
5 IPI00027547 DCD Dermcidin 279 11277 
6 IPI00025753 DSG1 Desmoglein-1 222 113644 
7 IPI00643920 TKT cDNA FLJ54957, highly similar to Transketolase 153 68698 
8 IPI00216694 PLS3 Plastin-3 141 70766 
9 IPI00022434 ALB Putative uncharacterized protein ALB 135 71658 
10 IPI00300074 FARSB Phenylalanyl-tRNA synthetase beta chain 126 66088 
11 IPI00015614 PRSS3 Isoform A of Trypsin-3 125 32508 
12 IPI00012442 G3BP1 Ras GTPase-activating protein-binding protein 1 120 52132 
13 IPI00217182 DSP Isoform DPII of Desmoplakin 111 259957 
14 IPI00020599 CALR Calreticulin 111 48112 
15 IPI00008603 ACTA2 Actin, aortic smooth muscle 108 41982 
16 IPI00789324 JUP cDNA FLJ60424, highly similar to Junction plakoglobin 106 62577 
17 IPI00179953 NASP Isoform 1 of Nuclear autoantigenic sperm protein 105 85186 
18 IPI00025874 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 86 72733 
19 IPI00217975 LMNB1 Lamin-B1 75 66368 
20 IPI00294879 RANGAP1 Ran GTPase-activating protein 1 70 63502 
21 IPI00000690 AIFM1 Isoform 1 of Apoptosis-inducing factor 1, mitochondrial 66 66859 
22 IPI00179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 58 17953 
23 IPI00009771 LMNB2 Lamin-B2 58 69906 
24 IPI00398625 HRNR Hornerin 54 282228 
25 IPI00219077 LTA4H Isoform 1 of Leukotriene A-4 hydrolase 50 69241 
26 IPI00216298 TXN Thioredoxin 50 11730 
27 IPI00465233 EIF3L Eukaryotic translation initiation factor 3, subunit E interacting pro 49 70857 
28 IPI00032325 CSTA Cystatin-A 48 11000 
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Table 2.7: MS results from Probe sample (70 kDa) 
rank prot_acc prot_desc (Tax_Id=9606 Gene_Symbol) prot_score prot_mass 
1 IPI00304925 HSPA1A;HSPA1B Heat shock 70 kDa protein 1A/1B 1604 70009 
2 IPI00012912 CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial 1421 73730 
3 IPI00911039 HSPA1A;HSPA1B cDNA FLJ54408, highly similar to Heat shock 70 kDa protein 1 1340 63885 
4 IPI00644712 XRCC6 ATP-dependent DNA helicase 2 subunit 1 1242 69799 
5 IPI00004860 RARS Isoform Complexed of Arginyl-tRNA synthetase, cytoplasmic 1191 75331 
6 IPI00217975 LMNB1 Lamin-B1 843 66368 
7 IPI00221226 ANXA6 Annexin A6 613 75826 
8 IPI00643920 TKT cDNA FLJ54957, highly similar to Transketolase 500 68698 
9 IPI00411937 NOP56 Nucleolar protein 56 468 66009 
10 IPI00300074 FARSB Phenylalanyl-tRNA synthetase beta chain 467 66088 
11 IPI00216694 PLS3 Plastin-3 423 70766 
12 IPI00025874 RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 416 72733 
13 IPI00012442 G3BP1 Ras GTPase-activating protein-binding protein 1 409 52132 
14 IPI00017617 DDX5 Probable ATP-dependent RNA helicase DDX5 391 69105 
15 IPI00020127 RPA1 Replication protein A 70 kDa DNA-binding subunit 376 68095 
16 IPI00007084 SLC25A13 Calcium-binding mitochondrial carrier protein Aralar2 353 74129 
17 IPI00305166 SDHA cDNA FLJ61478, highly similar to Succinate dehydrogenase (ubiquinone)  347 72641 
18 IPI00217143 SDHA SDHA protein 347 56716 
19 IPI00294879 RANGAP1 Ran GTPase-activating protein 1 296 63502 
20 IPI00219077 LTA4H Isoform 1 of Leukotriene A-4 hydrolase 276 69241 
21 IPI00027547 DCD Dermcidin 276 11277 
22 IPI00658000 IGF2BP3 Isoform 1 of Insulin-like growth factor 2 mRNA-binding protein 3 224 63666 
23 IPI00064328 PRMT5 protein arginine methyltransferase 5 isoform b 192 71275 
24 IPI00022434 ALB Putative uncharacterized protein ALB 179 71658 
25 IPI00552546 C10orf119 Isoform 2 of UPF0557 protein C10orf119 166 72703 
26 IPI00179953 NASP Isoform 1 of Nuclear autoantigenic sperm protein 163 85186 
27 IPI00021338 DLAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate de 154 68953 
28 IPI00003886 GNL3 Isoform 2 of Guanine nucleotide-binding protein-like 3 144 60503 
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29 IPI00022395 C9 Complement component C9 131 63133 
30 IPI00100460 DARS2 Aspartyl-tRNA synthetase, mitochondrial 123 73516 
31 IPI00032304 PLS1 Plastin-1 113 70209 
32 IPI00018140 SYNCRIP Isoform 1 of Heterogeneous nuclear ribonucleoprotein Q 104 69560 
33 IPI00394679 WHSC2 Wolf-Hirschhorn syndrome candidate 2 protein 104 58462 
34 IPI00008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 99 63417 
35 IPI00171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 93 77464 
36 IPI00027462 S100A9 Protein S100-A9 92 13234 
37 IPI00019463 EIF2AK2 Interferon-induced, double-stranded RNA-activated protein kinase 88 62056 
38 IPI00306043 YTHDF2 Isoform 1 of YTH domain family protein 2 86 62296 
39 IPI00013894 STIP1 Stress-induced-phosphoprotein 1 86 62599 
40 IPI00012074 HNRNPR Isoform 1 of Heterogeneous nuclear ribonucleoprotein R 81 70899 
41 IPI00179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 78 17953 
42 IPI00008603 ACTA2 Actin, aortic smooth muscle 78 41982 
43 IPI00219221 LGALS7;LGALS7B Galectin-7 78 15066 
44 IPI00642862 PPIL4 Peptidyl-prolyl cis-trans isomerase-like 4 76 57189 
45 IPI00382470 HSP90AA1 Isoform 2 of Heat shock protein HSP 90-alpha 66 98099 
46 IPI00009057 G3BP2 Isoform A of Ras GTPase-activating protein-binding protein 2 57 54088 
47 IPI00014424 EEF1A2 Elongation factor 1-alpha 2 54 50438 
48 IPI00166768 TUBA1C TUBA1C protein 53 36719 
49 IPI00296563 GUF1 GTP-binding protein GUF1 homolog 52 74281 
50 IPI00163505 RBM39 Isoform 1 of RNA-binding protein 39 51 59343 
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The identities of the top three proteins found by MS were confirmed by repeating 
the biotin pull-down experiment and Western blotting with specific antibodies (Figure 
2.5). The probe was also able to pull down 14DM, but this binding was barely detectable 
(Figure 2.6), consistent with previous reports that show itraconazole has minimal activity 
against human 14DM15,16. Interestingly, when the photolabeling experiment was repeated 
in HUVEC, it appeared that the vast majority of the probe bound to VDAC1 (Figure 
2.7), suggesting that in endothelial cells the other two proteins are minor targets, and 














Figure 2.5: Western blot validation of the proteins identified by MS.  After 
photolabeling and biotin pull-down in 293T cells, Western blots were performed using 
antibodies against each of the 3 highest scoring proteins by MS. The results demonstrate 
that the proteins identified by MS were specifically pulled down by the probe and 









Figure 2.6: Western blot of 14-alpha demethylase after pull down by the itra probe. 
14DM labeling by the itra probe was detectable by western blot after biotin pull-down, 
but the amount of protein detected compared with the input is much lower than for the 

















Figure 2.7: Live-cell photoaffinity labeling in 293T vs. HUVEC. The photoaffinity 
labeling experiment was repeated in HUVEC, where the vast majority of the probe bound 




Validation experiments narrow down targets 
To determine which of the three newly identified itraconazole-binding proteins 
might be relevant to its antiangiogenic mechanism of action, we first knocked down each 
protein individually in HUVEC. Two shRNA sequences were designed for each target 
and packaged in lentivirus for delivery to the cells. After 2-3 days transduction, the cells 
were assessed for any changes in the phenotypes associated with itraconazole, including 
cell proliferation (by thymidine incorporation), cholesterol distribution (by filipin 
staining), mTOR activity and VEGFR2 glycosylation (by Western blot). All of the 
knockdown cells showed decreased rates of cell proliferation to varying degrees, 
although none showed a significant difference in sensitivity to itraconazole (Figures 2.8 
and 2.9). None of the knockdown cells showed induction of NPC phenotype or changes 
in VEGFR2 glycosylation (data not shown). However, knockdown of VDAC1 and CPT2 
decreased basal mTOR activity as measured by phosphorylation of S6K (Figure 
2.10a,b), whereas mEH knockdown did not affect mTOR activity (Figure 2.10c). This 
result suggested that VDAC1 and/or CPT2 might be relevant to the mechanism of mTOR 









Figure 2.8: Knockdown of the three putative targets in HUVEC. Cells were treated 
with lentivirus for 3 days before expression of the targets was measured by Western blot. 
Two different shRNA sequences were used for each target protein. Sc = scrambled 
shRNA; C1 = CPT2 sh#1; C2 = CPT2 sh#2; M5 = mEH sh#5; M8 = mEH sh#8; V1 = 














Figure 2.9: Knockdown cells display decreased proliferation rate in HUVEC. 
Proliferation of the lentivirus-transduced cells was assessed by thymidine incorporation 
assay. The cells displayed a decrease in the overall rate of proliferation (total cpm), with 
VDAC1 knockdown cells having the lowest proliferation rate. However, none of the cells 
showed a significant difference in their sensitivity to proliferation inhibition by itra.  
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Figure 2.10: Effect of knockdowns on mTOR signaling in HUVEC. Knockdown of 
A) VDAC1 and B) CPT2 both caused a significant decrease in basal S6K 
phosphorylation, indicating mTOR was inhibited in these cells. C) Knockdown of mEH 
does not change S6K phosphorylation, as compared with knockdown of VDAC1.   
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The relevance of mEH was further ruled out by demonstrating that another azole 
antifungal drug, miconazole, could compete with binding of the itraconazole probe to 
mEH, but an analog of itraconazole lacking the azole ring (triazole-deleted [TD]-itra) 
could not (Figure 2.11). This result suggested that the binding to mEH was likely 
mediated by the azole ring and not specifically by itraconazole itself. Since the 
antiangiogenic activity of itraconazole is unique among the azole antifungals tested, it 























Figure 2.11: Competition of the probe binding to mEH is mediated by the azole ring 
of itraconazole. The photoaffinity labeling experiment was performed using TD-itra or 
miconazole as competitors, and the labeled proteins were either detected by fluorescence 
gel scan (left) or pull-down followed by Western blot (right). These results demonstrate 
that itraconazole is able to compete with the probe binding to mEH, but TD-itra is not.   
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CPT2 is a resident protein of the inner mitochondrial membrane (IMM), where it 
is involved in transporting fatty acids into the mitochondria to undergo beta-oxidation33. 
To assess whether itraconazole is able to inhibit CPT2 activity in cells, we measured 
beta-oxidation in the presence and absence of itraconazole by observing the conversion of 
14C-oleic acid to 14CO2. Compared with the positive control inhibitor etomoxir, which 
significantly inhibited beta-oxidation in this assay, itraconazole did not have any obvious 
effect (Figure 2.12). In addition, there was no observable build-up of palmitoyl-carnitine 
in itraconazole-treated cells measured by LC-MS, which would be expected if the 
enzyme’s activity were inhibited by itraconazole (data not shown). Thus, with no 
evidence of any effect of itraconazole on CPT2 function in cells, we concluded that CPT2 
is also unlikely to be a physiologically relevant target of itraconazole and subsequently 
















Figure 2.12: Itraconazole does not inhibit fatty acid oxidation in HUVEC. Compared 
with DMSO treatment alone, etomoxir inhibits β-oxidation almost to control levels, while 
10 µM itraconazole has no effect.  
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VDAC, also known as mitochondrial porin, is a β barrel protein channel that sits 
in the outer mitochondrial membrane (OMM) and regulates the movement of ions and 
small metabolites into and out of the mitochondria. First, to confirm the specificity of 
itraconazole’s binding to VDAC1, we repeated the photoaffinity labeling and pull-down 
experiment in HUVEC and assessed binding to another β barrel protein of the OMM, 
Tom 4034, by Western blot (Figure 2.13). As expected, there was no labeling of Tom 40 
by the itraconazole probe, showing that the binding between itraconazole and VDAC1 is 
indeed specific and not due to non-specific hydrophobic interactions or accumulation in 
the membrane. 
There are three isoforms of VDAC found in mammals: VDAC1, VDAC2, and 
VDAC335. Although VDAC1 was the primary isoform identified by MS and Western 
blot as binding to the itraconazole probe, we wanted to assess whether this binding was 
isoform specific. We therefore expressed each individual VDAC isoform with a C-
terminal V5 tag in 293T cells and repeated the pull-down experiment. By Western 
blotting with a V5 antibody, we were able to observe clear labeling of the exogenously 
expressed VDAC1, whereas labeling of VDAC2 and VDAC3 was barely detectable 
(Figure 2.14), suggesting that binding of the itraconazole probe is selective for VDAC1 

















Figure 2.13: The itraconazole probe does not bind to Tom40. Biotin pull-down and 
Western blot with antibodies against VDAC1 and another β-barrel protein of the outer 
mitochondrial membrane, Tom40, shows that the binding of the itraconazole probe is 


























Figure 2.14: The itraconazole probe selectively binds to VDAC1 over VDAC 2 or 3. 
Each individual VDAC isoform with a C-terminal V5 tag was expressed in 293T cells 
before labeling with the itraconazole probe and biotin pull-down. Detection of the 
expressed protein by western blotting with a V5 antibody revealed clear labeling of 
VDAC1 and only very faint labeling of VDACs 2 and 3 (indicated by arrows).  
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Itraconazole activates AMPK in HUVEC 
The primary cellular function of VDAC is to regulate mitochondrial function by 
controlling the movement of ions and small metabolites across the OMM36,37. Because of 
the central role of mitochondria in a myriad of cellular processes, we reasoned that there 
is likely to be a pathway by which mitochondrial function is connected to mTOR activity; 
however, this link has not been directly demonstrated38. mTOR is known to be regulated 
by multiple upstream signaling pathways, responding to changes in cellular nutrient 
availability and energy stress. One of these is the 5’ AMP-activated protein kinase 
(AMPK) pathway, which is activated by an increase in the cellular AMP:ATP ratio, 
indicating that energy levels are low39,40. Because VDAC is known to regulate 
mitochondrial ATP production by transporting ADP and ATP across the OMM37, we 
hypothesized that itraconazole binding to VDAC1 might perturb ATP production and 
cause activation of the AMPK pathway. 
 We therefore examined the effect of itraconazole on AMPK activity in HUVEC. 
Upon binding of AMP to the γ-subunit of the heterotrimeric AMPK complex, a 
conformational change takes place that allows phosphorylation of threonine 172 of the α-
subunit to occur, leading to activation of its kinase activity. As shown in Figure 2.15, 
treatment of HUVEC with itraconazole increased the phosphorylation of AMPKα at 
Thr172 within 5 minutes of drug treatment, with maximal activation occurring after 15 
minutes, after which time levels dropped slightly but remained elevated compared to 
control. The level of AMPK phosphorylation induced by itraconazole at 15 minutes was 
similar to that of a positive control compound, thapsigargin41. Importantly, 
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phosphorylation of the mTOR substrate S6K did not begin to decrease until 15 minutes 
after itraconazole treatment, and was maximally inhibited after 30 minutes. The slower 
onset of mTOR inhibition by itraconazole suggests that AMPK activation is likely 
upstream of mTOR inhibition by itraconazole, consistent with a possible causal 


















Figure 2.15: Itraconazole activates AMPK prior to the onset of mTOR inhibition in 
HUVEC. The activating phosphorylation of AMPKα increases within 5 min of 
itraconazole treatment, but mTOR inhibition is not observed until 15 min after 
itraconazole treatment, suggesting that mTOR is downstream of AMPK.  
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Activation of AMPK leads to restoration of cellular energy levels by upregulating 
ATP-producing pathways and downregulating ATP-consuming ones. One canonical 
substrate of AMPK is acetyl-CoA carboxylase 1 (ACC1), which is involved in the 
synthesis of fatty acids during times of excess energy availability and is inactivated upon 
phosphorylation at Serine 79 by AMPK42. As expected, itraconazole treatment also led to 
increased phosphorylation of ACC1 in HUVEC (Figure 2.16), demonstrating that 
stimulation of AMPKα by itraconazole indeed increases the kinase activity of AMPK and 
affects downstream signaling pathways.  
AMPK activation is known to lead to mTOR inhibition through direct 
phosphorylation of two mTOR regulatory proteins: tuberous sclerosis 2 (TSC2) and the 
regulatory associated protein of mTOR (raptor)38,40. Phosphorylation of raptor on Serine 
792 by AMPK increases the association of raptor with the scaffold protein 14-3-3, 
leading to dissociation and inactivation of the mTOR complex 1. We found that treatment 
of HUVEC with itraconazole led to an increase in the phosphorylation of raptor at Serine 
792, similar to that induced by the known AMPK activating compound 2-deoxyglucose 
(2DG) (Figure 2.16). Interestingly, we did not observe increased phosphorylation of 
TSC2 by either itraconazole or 2DG in these cells, indicating that inhibition of mTOR by 






















Figure 2.16: Itraconazole increases phosphorylation of AMPK substrates. 
Phosphorylation of the AMPK substrates ACC and raptor increases dose-dependently 
with itraconazole treatment, concomitant with a decrease in S6K phosphorylation. 
However, phosphorylation of TSC2 at Ser1387 is not affected by either itraconazole or 
2DG under the same conditions, suggesting that itraconazole’s inhibition of mTOR is 
mediated by raptor rather than TSC2.  
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 Given that AMPK activation leads to mTOR inhibition, and mTOR positively 
regulates proliferation, we wanted to specifically test the effect of AMPK activation on 
proliferation in HUVEC. A769662 is a direct and specific activator of AMPK, which 
binds in the interface between the AMPK α- and β-subunits and allosterically activates 
the complex43.  We therefore tested A769662 in HUVEC and found that it inhibited 
proliferation with an IC50 of 73 µM (+/- 8.34, SEM) (Figure 2.17a). Conversely, 
inhibition of AMPK using the small molecule AMPK inhibitor Compound C 
significantly reversed the proliferation inhibition caused by itraconazole in HUVEC 
(Figure 2.17b). These results demonstrate a causal relationship between AMPK 
activation and proliferation inhibition in HUVEC and support the hypothesis that 










Figure 2.17: AMPK activation causes proliferation inhibition in HUVEC. 
	
(A) HUVEC were treated with varying concentrations of A769662 for 24 hours before 
being pulsed for 6 hours with 3H-thymidine. The average IC50 from 3 independent 
experiments was 73 µM +/- 8.34 (SEM). (B) HUVEC were pretreated with 10 µM 
Compound C for 30 minutes before being treated with varying concentrations of 
itraconazole for 24 hours. Cells were then pulsed for 6 hours with 3H-thymidine. Results 
shown are averaged from 3 independent experiments, and error bars represent SEM. 
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To further verify the activation of AMPK by itraconazole in cells and to follow 
the time course of AMPK activation in higher resolution, we used a genetically encoded 
FRET-based biosensor which allows AMPK activity to be measured directly in real 
time26. The reporter contains a phosphorylation motif identified through a positional 
peptide library screen27 and undergoes a conformational change upon phosphorylation by 
AMPK leading to an increase in the yellow/cyan FRET emission ratio of the reporter. 
Consistent with the results obtained by Western blot, 2 µM itraconazole caused a rapid 
increase in FRET ratio beginning about 5 minutes after drug addition and peaking 
between 10-15 minutes, before slowly tapering off again (Figure 2.18a,b). After 30 
minutes, 20 mM 2DG was added to maximize the FRET response of the reporter. From 
this experiment, we determined that 2 µM itraconazole was able to activate AMPK to 
approximately 70% of the maximum achievable response induced by 20 mM 2DG. The 
specificity of the FRET reporter response was confirmed by using a version of the 
reporter containing a T/A mutation in the phosphorylation motif, which renders it 
insensitive to AMPK activation; as expected, neither itraconazole nor 2DG induced any 
changes in the emission ratio of the mutated reporter (Figure 2.18c). Taken together, 
these results confirmed that itraconazole causes activation of AMPK and its downstream 

































Figure 2.18: A FRET-based AMPK activity reporter demonstrates increased AMPK 
activation in live cells. A) HUVEC expressing the AMPK-activity reporter ABKAR 
show an increased yellow/cyan emission ratio after treatment with 2 µM itraconazole (*); 
this increase peaks 10–15 min after treatment. The effect of itraconazole was 
∼70% of the maximal response of the reporter induced by 20 mM 2DG (^). (B) 
Pseudocolor images of an itraconazole-treated HUVEC cell expressing ABKAR. (C) 
Cells expressing the reporter with a T/A mutation in the substrate motif, which cannot be 
phosphorylated by AMPK, show no response to itraconazole (*) or 2DG (^) treatment.  
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AMPK activation by itraconazole is caused by an increase in AMP:ATP ratio  
The activating phosphorylation of AMPKα at Thr172 is known to be carried out 
by two upstream kinases, LKB1 and CaMKKβ44. LKB1 is thought to be constitutively 
active, but it can only efficiently phosphorylate AMPKα after the conformational change 
induced by AMP binding to the γ subunit when AMP:ATP ratios are high. On the other 
hand, CaMKKβ is a calmodulin-dependent kinase that is activated by increased 
intracellular calcium levels. To determine which of these two mechanisms is involved in 
AMPK activation by itraconazole, we measured AMP, ADP, and ATP levels in extracts 
of DMSO- or itraconazole-treated cells by LC-MS/MS. We found that itraconazole 
treatment caused a rapid increase in both AMP:ATP and ADP:ATP ratios (Figure 
2.19a,b) compared with DMSO treatment, indicating a drop in cellular energy levels after 
itraconazole treatment. Further, the activation of AMPK by itraconazole was not blocked 
in cells pretreated with the CaMKKβ inhibitor STO-609, whereas activation by the 
calcium ionophore ionomycin was reversed (Figure 2.19c), suggesting that unlike 
ionomycin, itraconazole does not activate AMPK through a calcium-dependent 
mechanism.  
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Figure 2.19: Itraconazole-induced AMPK activation is the result of the increased 
AMP:ATP ratio. Itraconazole treatment increases the AMP:ATP (A) and ADP:ATP (B) 
ratio in HUVEC, as measured by LC-MS/MS. Cells were treated with 0.5 or 2 µM 
itraconazole for 2 min followed by metabolite extraction. Error bars represent SEMs of 
three independent experiments. A statistically significant increase in AMP:ATP or 
ADP:ATP was calculated by paired, one-tailed t test. *P < 0.05, ***P < 0.001. (C) 
Pretreatment of HUVEC with the CaMKKβ inhibitor STO-609 (30 min, 10 µM) does not 
prevent activation of AMPK by itraconazole (15 min, 2 µM), as opposed to the calcium 
ionophore ionomycin (15 min, 3 µM), indicating that itraconazole does not activate 
AMPK through a calcium/calmodulin/CaMKKβ-dependent pathway.  
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In addition, two commonly used cell lines which lack LKB1, A549 and HeLa 
(Figure 2.20a), did not display any AMPK activation by itraconazole, and the effect on 
mTOR in these cell lines was also greatly diminished (Figure 2.20b-d), further 
demonstrating that AMPK activation is upstream of mTOR inhibition by itraconazole. In 
contrast to itraconazole, ionomycin was able to activate AMPK in A549 and HeLa cells, 
demonstrating that an increase in cytosolic calcium was able to induce AMPK activation 
in these cells and again suggesting that itraconazole does not act through a calcium-
dependent mechanism (Figure 2.20e). Taken together, these results strongly suggest that 
activation of AMPK by itraconazole in HUVEC is caused by an increase in cellular 

























     











Figure 2.20: LKB1-deficient cells are insensitive to itraconazole. (A) A549 and HeLa, 
two commonly used cell lines which are reported to be LKB1-deficient, do not express 
LKB1 as measured by western blot. (B) HUVEC, (C) A549, and (D) HeLa cells were 
treated with 5 µM itraconazole for the indicated times (in hours except where indicated) 
or 100 µM A769662 for 1 hour. (E) A549 and HeLa cells were treated with either 5 µM 
itraconazole or 3 µM ionomycin for 15 minutes. Ionomycin activates AMPK in these cell 
lines while itraconazole does not.  
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VDAC1-/- cells are resistant to AMPK activation and mTOR inhibition by 
itraconazole 
 We next sought to determine whether the activation of AMPK by itraconazole can 
be explained by the observed binding to VDAC1. Because the efficiency of VDAC1 
knockdown achieved in HUVEC by lentivirus was not high, we sought to generate 
VDAC1 null cells for further studies with itraconazole. However HUVEC are primary 
cells that only survive several passages in culture, rendering it unsuitable for such genetic 
manipulation as gene knockout. We thus turned to VDAC1 knockout MEFs which were 
generated previously19. VDAC1 knockout was complete as confirmed by Western blot 
(Figure 2.21a). Wild type and VDAC1-/- MEFs were treated in parallel with itraconazole 
and assessed for AMPK activation and mTOR inhibition by Western blot analysis. 
Consistent with what was seen in VDAC1 knockdown HUVEC, basal mTOR signaling 
appeared to be lower in VDAC1-/- cells than the wild type. In wild type MEFs, 5 µM 
itraconazole robustly activated AMPK, as measured by ACC phosphorylation, and also 
inhibited mTOR, as measured by S6K phosphorylation. Strikingly, VDAC1-/- cells were 
completely resistant to AMPK activation by 5 µM itraconazole, and they also showed 
significantly less mTOR inhibition (Figure 2.21a). The insensitivity to itraconazole was 
also sustained for up to 24 h, demonstrating that there is no change in the time course of 
AMPK activation in these cells. In contrast, 2DG, which inhibits glycolysis and thus 
should activate AMPK independently of VDAC1 status, was still able to activate AMPK 
in VDAC1-/- cells, demonstrating that the lack of AMPK response in VDAC1-/- cells is 
specific to itraconazole’s mechanism (Figure 2.21b). These results clearly draw a direct 
link between VDAC1 function and AMPK activation/mTOR inhibition and strongly 
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suggest that direct binding to VDAC1 mediates the activation of AMPK and inhibition of 















Figure 2.21: VDAC1-knockout cells are resistant to AMPK activation by 
itraconazole. (A) Itraconazole (5 µM) causes robust activation of AMPK and inhibition 
of mTOR in wild-type MEFs, whereas VDAC1-knockout (VDAC1−/−) MEFs treated 
with itraconazole display no activation of AMPK and markedly reduced inhibition of 
mTOR. (B) Itraconazole has no effect in VDAC1−/− cells, whereas 2DG activates 
AMPK in both WT and VDAC1−/− cells, demonstrating that the lack of AMPK 
activation in VDAC1−/− is specific to the mechanism of itraconazole.  
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A known VDAC inhibitor, erastin, also activates AMPK and inhibits mTOR and 
proliferation of HUVEC 
It has been reported previously that the small molecule erastin also binds to 
VDAC45. We therefore tested whether erastin was also able to activate AMPK and inhibit 
mTOR in HUVEC. Cells were treated with a range of concentrations of erastin and 
itraconazole for 30 minutes before harvesting. Indeed, erastin dose-dependently increased 
AMPK activation as measured by ACC phosphorylation, similar to itraconazole, albeit 
with a significantly lower potency (Figure 2.22a). Erastin also inhibited mTOR signaling 
as measured by S6K phosphorylation. We then tested erastin for inhibition of HUVEC 
proliferation, and again found it to be active but less potent than itraconazole, with an 
IC50 of ~1.5 µM (Figure 2.22b). These results further suggest that binding to VDAC 
likely mediates the AMPK activation of both compounds. In support of this hypothesis, 
erastin also partially competed binding of the itraconazole probe to VDAC in HUVEC 
(Figure 2.22c), suggesting the two drugs likely bind to the same site on the channel.  
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Figure 2.22: The known VDAC antagonist erastin induces effects similar to those of 
itraconazole in HUVEC. (A) HUVEC were treated with erastin for 30 min at the 
indicated concentrations. Erastin, similar to itraconazole, dose-dependently activates 
AMPK and inhibits mTOR in HUVEC. (B) Erastin also inhibits HUVEC proliferation, 
with an IC50 of about 1.5 µM. (C) Erastin competes with binding of the itraconazole 
probe to VDAC in HUVEC.   
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Correlation between VDAC1 binding and HUVEC inhibition by itraconazole 
analogs 
One way of determining the physiological relevance of a drug target is to see 
whether there is a pharmacological correlation between binding of different analogs of 
the drug to the target and their cellular activity46. As previously reported, miconazole, 
terconazole, and fluconazole have IC50 values for HUVEC proliferation of about 2.5, 7, 
and >100 µM, respectively8. We thus performed the pull-down assay using pretreatment 
with high concentrations of these three drugs (20 µM miconazole/terconazole, 50 µM 
fluconazole) as competitors. Accordingly, 20 µM miconazole was able to partially 
compete with binding of the itraconazole probe to VDAC1, consistent with its moderate 
potency against HUVEC proliferation. However, terconazole and fluconazole were 
unable to compete with binding at the concentrations tested, suggesting that these less 
active analogs of itraconazole do not bind to VDAC1 appreciably (Figure 2.23a).  In 
contrast, an analog of itraconazole that lacks the triazole moiety (triazole-deleted 
itraconazole or TD-itra) retains activity in HUVEC (Figure 2.23b-d) and was also able to 
compete with binding of the itraconazole probe to VDAC1. Further, the binding of these 
compounds to VDAC1 also correlated with their ability to activate AMPK (Figure 2.23e). 
Collectively, these results further support the notion that VDAC1 is a physiologically 
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Figure 2.23: Inactive azoles do not bind VDAC1, but non-azole analog does. A) The 
ability of itraconazole-like molecules to bind to VDAC1 was assessed by their ability to 
compete with binding of the itraconazole probe to VDAC1. Cells were treated with 
DMSO alone (D), probe alone (P), or probe plus itraconazole (Ita), miconazole (Mic), 
terconazole (Ter), Fluconazole (Flu), or analog TD-itra (shown in panel b) at the 
indicated concentrations. B) Chemical structure of TD-itra. C) Dose-response curves of 
itraconazole and TD-itra against HUVEC proliferation. D) TD-itra is able to activate 
AMPK and inhibit mTOR in HUVEC after a 15-minute treatment. E) Compounds that 
bind to VDAC1 also activate AMPK.  
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Itraconazole increases the rate of calcium-induced mitochondrial swelling 
It has previously been observed that erastin increases the permeability of isolated 
mitochondria to calcium ions (Wenzhi Tan and Marco Colombini, unpublished). Because 
VDAC is known to be the main point of passage in the OMM for calcium ions, the rate of 
calcium entry into mitochondria may also be considered a measure of VDAC function. 
Calcium entry through VDAC causes mitochondrial swelling, and the rate of this 
swelling, which is easily monitored by a change in absorbance at 400 nm, is thus 
proportional to the rate of calcium transport. We therefore tested whether itraconazole 
could also induce the same effects as erastin in this calcium-induced mitochondrial 
swelling assay. Freshly isolated rat liver mitochondria were preincubated with drugs for 
10 minutes before addition of calcium and monitored at 400 nm. The absorbance was 
plotted over time, and the initial slope after calcium addition was considered the 
maximum rate of swelling. We found that itraconazole caused a dose-dependent increase 
in the rate of calcium-induced mitochondrial swelling, similar to erastin (Figure 2.24). 
The fact that another VDAC inhibitor exhibited similar effects on AMPK and mTOR in 
endothelial cells as well as calcium permeability in isolated mitochondria provides strong 























Figure 2.24: Itraconazole and erastin increase the rate of calcium–induced 
mitochondrial swelling. A) Purified rat liver mitochondria were preincubated with 
itraconazole or erastin at the concentrations shown for 10 minutes before the addition of 
calcium, and mitochondrial swelling was monitored at 400 nm. The initial rate of 
swelling was calculated by linear fitting. A representative plot of absorbance vs. time is 
shown for DMSO treated and 5 µM itraconazole-treated mitochondria. B) Itraconazole 
and erastin significantly increase the rate of calcium-induced mitochondrial swelling as 
compared to DMSO treatment. Error bars represent SEM of 4-5 experimental replicates. 
Statistically significant increase in swelling rate was calculated by an unpaired, one-tailed 
t-test. * p < 0.05, ** p < 0.01.  
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In vitro experiments with VDAC reconstituted in planar lipid bilayers 
 To determine whether the effects of itraconazole observed in cellular assays were 
due to a direct effect on intrinsic VDAC channel activity, we initiated a collaboration 
with Drs. Tatiana Rostovtseva and Sergei Bezrukov at the National Institutes of Health 
who specialize in electrophysiological measurements of VDAC channels. Experiments 
were performed with single channels to measure the conductance of the open and closed 
states of the channel, as well as the frequency of channel closure, in the presence of 
applied voltage with and without itraconazole. Single channel experiments were also 
performed in the presence of dimeric tubulin, a soluble factor that has been shown to 
directly block VDAC channels in vitro47, to determine whether itraconazole affected the 
interaction between VDAC and tubulin. In addition to the single channel experiments, 
multichannel experiments were also performed to measure the averaged gating properties 
of many channels.  
In the multichannel experiments, initial experiments performed at pH 7.4 showed 
a small but reproducible effect of itraconazole addition, which was to increase Gmin, or 
the minimum conductance achieved at high applied voltages (i.e. voltage gating) (Figure 
2.25a).  Because Gmin was already high under these conditions (channels were not gating 
significantly), making it difficult to detect a further increase in Gmin, we changed the 
conditions to increase gating by either decreasing the pH of the buffer (Figure 2.25b) or 
adding tubulin before drug (Figure 2.25c). In both cases, we were on multiple occasions 
able to observe a significant reversal of gating activity after itraconazole addition. 
Unfortunately, these effects were not reproducible in later experiments, and many 
attempts to determine the cause of the lost effect were unsuccessful.  
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Figure 2.25: Effect of itraconazole on purified VDAC channels in multichannel 
experiments. Conductance vs. Voltage (G/V) plots are used to visualize channel gating 
activity, i.e. the voltage-dependent closure of the channels. On the x-axis is the voltage 
applied to the channels (in mV), and on the y-axis, G/G0 is the observed conductance 
normalized to the conductance of the open state of the channel (G0 = 1).  A) Itraconazole 
treatment lead to a small increase in conductance at high applied voltages (increased 
Gmin); however the change was difficult to detect because the channels did not show 
significant gating activity before drug addition (Gmin ~ 0.8). B) Reducing the pH of the 
buffer to 6.0 significantly increases channel gating activity (Gmin ~ 0.4) and therefore the 
increase in Gmin after itraconazole treatment is more pronounced. C) Addition of tubulin 
(3.4 nM x 2 additions) similarly increases channel gating activity (Gmin ~ 0.75), and 
subsequent addition of itraconazole (5 µM x 2 additions) reverses the tubulin-induced 
gating back to control levels.  
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In the single channel experiments, we decreased the pH to ~6 to induce 
measurable gating activity at +/-50-60mV. Each voltage condition was recorded for 
approximately 10 minutes, and the Topen (channel open time), frequency of closure, and 
closed state conductances were measured. After recording each voltage for the control, 
DMSO or itraconazole (500 nM-10 µM) was added to both sides of the membrane. 
Several experiments (n = 9) were performed with a single VDAC channel at pH 6. There 
was a large degree of variability in gating activity from one channel to another, where 
some channels had measurable gating activity at 50 mV while others did not close until 
60 mV was applied. The direction and degree of gating asymmetry was also inconsistent, 
but this may be due in part to the sign of the voltage being applied at the time of channel 
insertion. In order to compare results from one experiment to another, the voltage that 
induced the most closures was used for measurements (generally negative voltage at cis 
side), and the frequency of closure (closures per minute, or CPM) was normalized to the 
control recorded at the beginning of each experiment.  
We found that in the majority of experiments, there was an increase in the 
frequency of closures and a corresponding decrease in Topen after itraconazole addition 
(Figure 2.26a). The effect was fairly consistent, but the degree of the effect was highly 
variable, ranging from 50-500% increase in CPM. In two out of nine experiments there 
was no effect of itraconazole addition, which could potentially be explained by isoform 
selectivity as the rat liver VDAC used contains a mixture of isoforms. Two experiments 
were also performed with DMSO alone, and a small increase in CPM (between 25-75%) 
was observed. However, in one experiment where the channel was recorded over an 
extended period of time with no drug addition, there was also a large increase in the 
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frequency of channel closures (Figure 2.26b). The fact that such an increase was not 
observed in all of the experiments indicates that this increase in gating over time does not 
occur with all channels; however, the possibility of such a large change in channel 
activity throughout the experiment makes it practically impossible to differentiate drug 
effects from fluctuating channel activity. Therefore, we could not conclude whether there 






























Figure 2.26: Effects of itraconazole on individual VDAC channels. Channel 
recordings showing the conductance (y-axis) over time (x-axis), where channel closure is 
detected as a downward spike in conductance. A) Compared with the control trace, the 
itraconazole-treated channel displays an increased frequency of channel closures. B) The 
frequency of closures of this particular channel increased dramatically over time on its 




To determine whether itraconazole may be affecting VDAC activity indirectly by 
altering lipid properties of the membrane, its effects on Gramicidin A channels, which are 
highly sensitive to any membrane perturbations, were measured. The voltage applied was 
150mV, and because of the low conductance and relatively long lifetime of these 
channels, the recordings were filtered at 200 Hz instead of 500 Hz. Channel lifetime and 
conductance were measured for control, DMSO (0.1%), and 10 µM itraconazole (0.2% 
DMSO) treatments. There was no obvious change in any of the treatment groups by eye. 
After data analysis, there appeared to be a very slight increase in channel lifetime and low 
conductance channel formation, but these effects were very small (Figure 2.27). These 
results suggest that itraconazole is either not altering membrane properties, or is not being 









































Figure 2.27: Effects of itraconazole on Gramicidin A channel conductance and 
lifetime. Histograms depicting the frequency of gramicidin channel conductance (A) and 




 Since itraconazole was identified as a novel inhibitor of angiogenesis, multiple 
newly initiated Phase 2 clinical studies and retrospective analyses have shown efficacy of 
itraconazole in the treatment of different types of cancer, suggesting that it is a promising 
antiangiogenic and anticancer drug candidate. Our previous mechanistic investigation 
ruled out lanosterol 14α-demethylase, the molecular target mediating the antifungal 
activity of itraconazole, as its antiangiogenic target. Using a phenotypic approach starting 
with the effect of itraconazole on the G1-S cell cycle transition of endothelial cells, we 
found that itraconazole specifically inhibited the mTOR signaling pathway by 
downregulating the kinase activity of mTORC1. The underlying molecular mechanism of 
inhibition of endothelial cell proliferation by itraconazole, however, has remained largely 
unknown. In the present study, we employed a photoaffinity labeling approach using a 
biologically active itraconazole photoaffinity probe in live cells to identify the 
mitochondrial outer membrane channel VDAC1 as a molecular target of itraconazole. 
Importantly, we were able to establish a previously unknown link between VDAC1 and 
mTOR via modulation of cellular AMP/ATP ratio and the activation of AMPK, 
elucidating the molecular basis of inhibition of mTOR activity by itraconazole.  
Classical approaches for direct identification of small molecule targets have 
largely relied on affinity-based methods46; however, for such an approach to be 
successful, the target protein must retain its ability to bind the small molecule outside of 
the native cellular environment. This is particularly problematic for integral membrane 
proteins, which often do not retain their native conformation upon cell lysis. The 
development of cell-permeable photoaffinity labels has helped to circumvent this issue by 
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allowing a probe to bind covalently to its target protein within the native environment of 
the cell, so that upon cell lysis the interaction is preserved and the target protein can be 
easily detected and isolated20. In this study, we utilized information from our previous 
structure-activity studies of itraconazole31,32 to design a cell-active photoaffinity probe, 
which enabled the identification of VDAC1 as a direct protein target of itraconazole. Had 
we used the conventional affinity pull-down approach, we may not have succeeded in this 
endeavor.  
It was once thought that the outer mitochondrial membrane (OMM) was 
essentially freely permeable, or “leaky”, to most small molecules. But more recently it 
has become clear that the permeability of the OMM is actually regulated by the channels 
that transport these molecules, the so-called Voltage Dependent Anion Channels48. It was 
predicted in 1979 that these channels would be involved in regulating mitochondrial 
metabolism49, and in the ensuing decades numerous studies have proven this to be true50–
54. The name of the channel is somewhat misleading, as although it was originally 
thought to be anion-selective, VDAC has also been shown to transport cations such as 
calcium, as well as numerous small metabolites including ATP, ADP, NADH, pyruvate, 
and others55,56. The voltage-dependent property of the channel when reconstituted into 
planar lipid bilayers leads to channel closure in the presence of ~40-50 mV applied 
voltage. However, the physiologic potential across the OMM is a matter of debate, and it 
remains unclear how this voltage-dependence translates to the signals which induce 
channel closure in the cell. The selectivity of VDAC channels is known to switch from 
anions to cations upon channel closure due to electrostatic changes within the pore; 
therefore, permeability to anions (such as ATP) and cations (such as calcium) are 
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inversely correlated55,57. Thus, the observation that itraconazole caused a decrease in 
cellular ATP levels and also increased mitochondrial permeability to calcium ions is 
consistent with this inverse relationship of VDAC charge selectivity.  
The discovery that itraconazole binds to a mitochondrial protein involved in 
regulating metabolism made sense in the context of the drug’s ability to activate AMPK.	
Mitochondria are critical for ATP production, and many small molecules which activate 
AMPK have been shown to inhibit mitochondrial function, including metformin, 
resveratrol, berberine, and rotenone 58–62. In order to produce ATP, ADP must enter the 
mitochondria through VDAC in the outer membrane and ANT (adenine nucleotide 
translocase) in the inner membrane, be converted to ATP through oxidative 
phosphorylation, and then exit the mitochondria again through ANT and VDAC. Indeed, 
it has been reported recently that VDAC closure reduces mitochondrial energy 
conversion and decreases cytosolic ATP:ADP ratios37. It is therefore logical that 
disruption of VDAC function by small molecules such as itraconazole would lead to a 
drop in cellular ATP levels, causing an increase in AMP:ATP ratio and the ensuing 
activation of AMPK.  
The connection between AMPK, mTOR, and angiogenesis has been firmly 
established in a number of previous studies. AMPK can regulate mTOR via two 
alternative pathways, mediated by the tumor suppressor protein TSC2 and the mTOR 
binding partner raptor38,40. Thus, upon phosphorylation by AMPK, TSC2 has an 
enhanced GTPase activity for its substrate Rheb, leading to mTOR inhibition. Unlike 
TSC2, phosphorylation of raptor leads to its association with 14-3-3, decreasing mTOR 
activity. Interestingly, we found activation of AMPK by itraconazole increased 
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phosphorylation of raptor but did not affect phosphorylation of TSC2. However, 
phosphorylation of raptor alone has been shown to be sufficient for inhibition of mTOR 
by AMPK in the absence of TSC240, so it is unnecessary for AMPK to affect mTOR 
activity via both TSC2 and raptor simultaneously. Thus, these results support the 
hypothesis that AMPK activation by itraconazole is upstream of mTOR inhibition.  
Several drugs modulating the AMPK pathway have also been evaluated as 
potential antiangiogenic and anticancer agents. The widely prescribed, AMPK-activating 
antidiabetic drug, metformin, has been shown to inhibit angiogenesis in vitro and in 
vivo63 and is currently being evaluated in several clinical trials for various types of 
cancer64. However, the concentrations of metformin required to activate AMPK in 
HUVEC are at least 1,000 times higher than those required of itraconazole (in the range 
of low mM63), suggesting that itraconazole might be significantly more effective than 
metformin at inhibiting angiogenesis in patients. Another drug in trials for cancer, the 
natural product curcumin, has also been shown to activate AMPK and inhibit mTOR65–67. 
Interestingly, a recent study demonstrated that it also interferes with VDAC1 function68, 
similar to itraconazole.  
In this study, we have demonstrated that the binding of itraconazole to VDAC1 
mediates its AMPK activation in endothelial cells. However, exactly how itraconazole 
binding affects VDAC1 function is a question that remains to be answered. In vitro 
VDAC activity assays, electrophysiological and crystallographic studies have been 
initiated, but are complicated by the fact that itraconazole is virtually insoluble in 
aqueous solution, and thus measurements of binding outside of the environment of the 
cell are difficult. This speaks to a major advantage of the live-cell photoaffinity labeling 
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approach, which is particularly well suited for hydrophobic molecules that would likely 
not interact with their target in solution. Another possibility is that itraconazole binding to 
VDAC1 does not affect its channel activity directly, but either requires or disrupts the 
interaction of another protein, with functional consequences. VDAC has been reported to 
interact with other proteins of diverse functions, including tubulin, hexokinase, ANT, 
Bcl-2, Bcl-XL, cyclophilin D, and TSPO, providing a multitude of other potential 
regulatory mechanisms47,69–73. Interestingly, itraconazole was shown to be synergistic 
with the cyclophilin-targeting drug cyclosporine A for angiogenesis inhibition74, so it is 
possible that simultaneous inhibition of VDAC1 and cyclophilin D could be the cause of 
this observed synergy.   
In summary, we have identified VDAC1 as a direct target of itraconazole and the 
AMPK signaling pathway as a key mediator of its inhibition of mTOR and endothelial 
cell proliferation. Thus, binding of itraconazole to VDAC1 leads to a decrease in 
mitochondrial ATP production and a corresponding increase in AMP:ATP ratio, which in 
turn leads to activation of AMPK. Phosphorylation of raptor by AMPK then causes 
inhibition of mTOR. These results elucidated a previously unknown connection between 
the mitochondrial VDAC1 channel and mTOR. The identification of VDAC1 as the 
molecular target of itraconazole will also facilitate the future discovery and development 
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Chapter 3: NPC1 as a Secondary Target of Itraconazole and a 
Dual-Targeted Mechanism of mTOR Inhibition 
 
3.1: Abstract  
 
In Chapter 2, I described the use of a photoaffinity probe of itraconazole to 
identify VDAC1 as its major binding partner in endothelial cells, as well as the validation 
studies connecting VDAC1 to the observed mTOR inhibition through activation of the 
AMPK pathway. However, the connection between VDAC1/AMPK and the previously 
described inhibition of cholesterol trafficking (i.e. Niemann-Pick type C, or NPC, 
phenotype induction) by itraconazole was not clear. Here, I demonstrate that NPC 
phenotype and AMPK activation are parallel effects of itraconazole, as other known NPC 
phenotype inducers do not activate AMPK, and other AMPK activators do not induce 
NPC phenotype. In addition, VDAC1 knockdown does not induce NPC phenotype in 
HUVEC, although it does inhibit mTOR, suggesting that another as yet unidentified 
target likely mediates the NPC phenotype induction by itraconazole. Using the 
photoaffinity probe to directly test whether itraconazole binds to either of the two critical 
NPC proteins (NPC1 and NPC2), I found that the probe does crosslink to NPC1 and the 
crosslinking is competed away by excess itraconazole, suggesting that it is a direct 
binding protein of itraconazole. We therefore hypothesized that by simultaneously 
inhibiting two targets that lead to mTOR inhibition via distinct mechanisms (AMPK 
activation and NPC phenotype induction), itraconazole inhibits mTOR much more 
potently than AMPK activators or NPC inducers alone. In support of this hypothesis, 
preliminary results show that the combination of a known AMPK activator (A769662) 
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and NPC inducer (U18666A) is synergistic for mTOR inhibition in HUVEC. Thus, 




14DM, lanosterol 14-α-demethylase; 2DG, 2-deoxyglucose; ACC, acetyl coA 
carboxylase; AMPK, AMP-activated protein kinase; CPT2, carnitine palmitoyltransferase 
2; DMSO, dimethyl sulfoxide; FRET, fluorescence resonance energy transfer; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; HUVEC, human umbilical vein endothelial 
cells; IC50, 50% inhibitory concentration; Itra, itraconazole; MEF, mouse embryonic 
fibroblast; mEH, microsomal epoxide hydrolase; mTOR, mechanistic target of 
rapamycin; NPC, Niemann-Pick type C; NTD, N-terminal domain; Raptor, regulatory 
associated protein of TOR; S6K, ribosomal protein S6 kinase; TD-itra, triazole deleted 
itraconazole; VDAC, voltage-dependent anion channel.  
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3.2: Introduction  
	
The mechanistic Target of Rapamycin (mTOR) pathway is a critical regulator of 
cell growth and proliferation. As such, it has been implicated in diseases such as cancer 
where growth and proliferation are dysregulated, and mTOR inhibitors have been 
pursued as cancer therapeutics1. The canonical inhibitor for which the pathway was 
named, rapamycin, inhibits the mTOR kinase directly by inducing dimerization of mTOR 
and FKBP12, physically preventing the assembly of mTOR complex 1 (mTORC1) that is 
required for phosphorylation of the downstream effectors such as S6 kinase (S6K) and 
eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1). Rapamycin and its 
analogs have been demonstrated to have antitumor and antiangiogenic activity; however, 
in practice their efficacy in clinical trials has been limited, likely due to insensitivity 
resulting from a signaling feedback loop that leads to activation of AKT upon prolonged 
treatment2,3. Other direct mTOR inhibitors have been designed which are mostly active 
site ATP-competitive kinase inhibitors, but like other drugs of this class these inhibitors 
often have off-target effects on other kinases and can lead to the development of 
resistance conferring mutations4. Thus, mTOR inhibitors with novel mechanisms may be 
useful in overcoming these limitations.  
The antifungal drug itraconazole was found to inhibit mTOR signaling and 
angiogenesis through a mechanism distinct from its antifungal target, 14-alpha 
demethylase (14DM), and unique to itraconazole over other azole antifungals5. Similarly 
to rapamycin, itraconazole induced an upregulation of p27 expression and 
downregulation of p21 in endothelial cells, and led to cell cycle arrest in the G1 phase6. It 
also inhibited the phosphorylation of mTORC1 substrates S6K and 4EBP1 with an IC50 
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between 100-300 nM, the same concentration range required for inhibition of HUVEC 
proliferation. Unlike rapamycin, however, itraconazole was also shown to have a striking 
effect on the intracellular distribution of cholesterol, as visualized by the fluorescent 
cholesterol-binding dye filipin. After itraconazole treatment, the cellular cholesterol 
rapidly became sequestered in perinuclear punctae that were shown to colocalize with the 
late endosomal-lysosomal marker LAMP-1, and was no longer distributed throughout the 
plasma membrane. This cholesterol distribution pattern is also observed in the cells of 
patients with a rare genetic disease called Niemann-Pick Type C (NPC) disease, where 
mutations in one of two lysosomal cholesterol-binding proteins (NPC1 and NPC2) 
prevents the release of cholesterol from the lysosome to the rest of the cell. The fact that 
rapamycin did not induce a similar NPC-like phenotype suggested that the cholesterol 
redistribution was not a downstream effect of mTOR inhibition. It was shown that 
knocking down either NPC1 or NPC2 led to inhibition of mTOR in HUVEC, and that 
two other NPC-inducing small molecules, U18666A and imipramine, also inhibited 
mTOR and proliferation in HUVEC, although at much higher concentrations than 
itraconazole (IC50 values of ~3 and 10 µM, respectively). Taken together, these results 
suggested that NPC phenotype was likely to be upstream of mTOR inhibition by 
itraconazole.  
 The identification of VDAC1 as a direct target of itraconazole, as described in 
Chapter 2, appeared to partially explain the inhibition of mTOR by itraconazole as a 
consequence of AMPK activation. However, it remained to be shown whether AMPK 
activation and NPC phenotype induction were interrelated or separate effects of 
itraconazole, and whether one or both of these effects was responsible for the 
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downstream mTOR inhibition and antiproliferative effects. In this chapter, I demonstrate 
that NPC phenotype and AMPK activation are in fact parallel effects of itraconazole, and 
that the photoaffinity probe of itraconazole directly binds to NPC1. I also demonstrate 
that combining the NPC inducer U18666A and the AMPK activator A769662 leads to a 
greater inhibition of mTOR than would be expected by adding the effects of the two 
drugs individually, suggesting that the simultaneous targeting of these two pathways 
synergistically inhibits mTOR. This unique dual-targeted mechanism of mTOR inhibition 
may underlie the higher potency of itraconazole for mTOR compared with other AMPK 
activators and NPC inducers, and its polypharmacology may help itraconazole to 




3.3: Materials and Methods 
	
Reagents and antibodies 
 Itraconazole was purchased from TCI Chemicals (I0732; Philadelphia, PA). 2DG 
was from LKT laboratories (D1859; St. Paul, MN). Filipin (F4767) was from Sigma-
Aldrich (St Louis, MO). Alexa Fluor 647-azide (A10277), TCEP (20490) and High 
Capacity Streptavidin Agarose beads (20359) were from Life Technologies (Grand 
Island, NY). Biotin-azide was from Click Chemistry Tools (AZ104-100; Scottsdale, AZ). 
TBTA was from Anaspec (63360-50; Fremont, CA). Copper Sulfate was from LabChem 
Inc (LC13440-1; Pittsburgh, PA). A769662 was from Abcam (ab120335; Cambridge, 
MA). Antibodies against ACC (3676), phospho-ACC Ser79 (3661), and phospho-p70 
S6K Thr389 (9205), were from Cell Signaling Technologies (Danvers, MA). Antibodies 
against p70 S6K (sc-8418), GAPDH (sc-20357), Tubulin (sc-5286), VDAC1 (sc-58649), 
and NPC2 (sc-33776) were from Santa Cruz Biotechnologies (Santa Cruz, CA). The 
antibody against NPC1 was from Proteintech (13926-1-AP; Chicago, IL).	
 
Cell culture 
 Primary HUVEC pooled from 4 donors (Lonza) were cultured in complete EGM-
2 (Lonza) and subcultured every 2 days at a density of 1:4, or 3 days at 1:8, and discarded 
after passage 8. HEK 293T, HeLa, and A549 were cultured in low glucose DMEM 
(Gibco; Gaithersburg, MD) supplemented with 10% filtered FBS (Gibco) and 1% 




 The plasmids used in this study were created by a previous member of the Liu lab 
(Dr. Jing Xu). NPC1 and NPC2 cDNAs were cloned into the pcDNA3.1 myc his-A 
vector digested with BamHI and XhoI, resulting in expression of the proteins with a C-
terminal myc-his tag. NPC1 NTD (aa 1-264) was cloned into the p3xflag CMV vector 
digested with NotI and XbaI, resulting in expression of the truncated protein with an N-
terminal 3x-FLAG tag.  
 
Filipin Staining 
 HUVEC 2-3 days post-transduction (as described in the Materials and Methods 
section of Chapter 2) were plated in an 8-well slide chamber at a density of 1000/well in 
1 mL of media and allowed to settle overnight. The media was removed and cells were 
fixed with 4% paraformaldehyde for 15 min at room temperature. Cells were then washed 
twice with PBS before being incubated with 500 µL of filipin solution (diluted from 5 
mg/ml DMSO stock solution to 50 µg/mL in PBS) for 1 h in the dark. The cells were then 
carefully washed twice more with PBS, mounted and covered with coverslip and 
observed using a 710NLO-Meta multiphoton microscope (Carl Zeiss, Thornwood, NY) 
using DAPI wavelengths (360/460 nm) at the Johns Hopkins Microscope Facility.  
 
Photoaffinity labeling  
 Photoaffinity labeling and pull-down experiments were performed as described in 
the Materials and Methods section of Chapter 2.  
 
Western blot 
 Western blotting was performed as described in the Materials and Methods 




AMPK activation and NPC phenotype induction are parallel effects of itraconazole 
 
AMPK is a well-established upstream regulator of mTOR signaling and, as 
described in Chapter 2, several pieces of evidence suggested that AMPK activation by 
itraconazole likely contributed to the observed mTOR inhibition in HUVEC. AMPK 
activation occurred rapidly after itraconazole treatment, as demonstrated by time-course 
Western blot and live cell imaging with a FRET reporter of AMPK activity, and shortly 
before the onset of mTOR inhibition. Increased phosphorylation of raptor on the AMPK 
phosphorylation site demonstrated that the known AMPK-activated feedback mechanism 
to inhibit mTOR was also triggered. In addition, cell lines in which AMPK activation did 
not occur (A549, HeLa, and VDAC1-/- MEFs) also displayed little to no mTOR 
inhibition by itraconazole. However, these results did not take into account the previously 
uncovered evidence that appeared to connect the cholesterol trafficking inhibition by 
itraconazole to mTOR. It remained a possibility that NPC phenotype induction by 
itraconazole somehow led to AMPK activation, or conversely that AMPK activation 
induced NPC phenotype by an unknown mechanism, which then led to mTOR inhibition.  
To address these possibilities, we therefore tested whether two other commonly 
used NPC phenotype-inducing compounds that had previously been shown to inhibit 
mTOR, U18666A and imipramine, could also activate AMPK in HUVEC. At 
concentrations where mTOR inhibition was clearly observed, there was no detectable 
activation of AMPK (Figure 3.1), demonstrating that inhibition of cholesterol trafficking 
alone is not sufficient to activate AMPK, and therefore that NPC phenotype is not 











Figure 3.1: Other NPC inducers do not activate AMPK. HUVEC were treated with 
the indicated concentrations of NPC inducing compounds U18666A and imipramine for 
1 hour. Neither compound had any observable effect on AMPK, as measured by ACC 
phosphorylation, at concentrations that inhibit mTOR.   
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We next tested whether other AMPK activators could induce NPC phenotype. 
Two AMPK activating compounds very commonly used in the literature are 2-
deoxyglucose (2DG) and metformin. 2DG is an analog of glucose that cannot undergo 
glycolysis and thus causes a drop in cellular energy levels by acting as a competitive 
inhibitor of glycolysis. Metformin inhibits mitochondrial ATP production through a 
mechanism that has been debated in the field but is now generally thought to involve 
inhibition of complex I of the respiratory chain7. Another compound that has been shown 
to activate AMPK and inhibit mTOR is the common drug aspirin8. Notably, aspirin 
displayed a similar biphasic time-course of mTOR inhibition as itraconazole, where there 
was a slight recovery of mTOR activity around 4-8 hours that dropped off again to 
complete inhibition after 24 hours (Figure 3.2). In addition, one study that used a 
clickable probe designed to detect proteins alkylated by aspirin included VDAC1 among 
the list of modified proteins9. These interesting results prompted the question of whether 
itraconazole and aspirin might share a common mechanism of mTOR inhibition. 
However, none of the three AMPK activating drugs induced NPC phenotype (data not 
shown), and neither aspirin nor metformin competed with binding of the itraconazole 
probe to VDAC1 (Figure 3.3), demonstrating that they activated AMPK through a 
different mechanism than itraconazole. Taken together, these results suggested that 










Figure 3.2: Itraconazole and aspirin both inhibit mTOR in HUVEC. HUVEC were 
treated with itra or aspirin for the indicated times. Both displayed a biphasic time-course 
of mTOR inhibition, where phosphorylation of S6K initially decreased rapidly, recovered 
















Figure 3.3: Neither aspirin nor metformin competes with binding of the itraconazole 
probe to VDAC1. The binding of the photoaffinity probe to VDAC1 (blue arrow) is 
competed away by itraconazole, but not by metformin or aspirin. (D = DMSO; P = Probe; 
C = Competition with Itraconazole; M = Competition with Metformin; A = Competition 
with aspirin)  
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NPC phenotype is not explained by the known targets of itraconazole 
 
We previously demonstrated that knockdown of VDAC1 in HUVEC inhibited 
mTOR and proliferation as compared to wild-type cells. To determine if these effects 
were related to the NPC phenotype, we visualized cholesterol in VDAC1 knockdown 
cells and found that there was no difference in the distribution of cholesterol in wild-type 
vs. knockdown cells. This result suggested that NPC phenotype induction by itraconazole 
was likely mediated by a target other than VDAC1. Similarly, mEH and CPT2 
knockdown did not affect cholesterol distribution in HUVEC. We also considered the 
possibility that inhibition of 14DM is responsible for NPC phenotype induction, as other 
azole antifungals were able to induce NPC phenotype at high concentrations6. However, 
the triazole-deleted itraconazole analog (TD-itra) was clearly able to induce NPC 
phenotype at 100 nM, suggesting that the azole ring was not required for this activity and 
thus not mediated by 14DM inhibition (Figure 3.4). These results led us to wonder if an 
additional target that had not yet been identified might be involved, and because the 
photoaffinity probe was also able to induce NPC phenotype (Figure 2.2c) we reasoned 









Figure 3.4: TD-itra induces NPC phenotype in HUVEC. HUVEC were treated with 
DMSO or TD-itra (2 µM) for 24 hours before staining with filipin to visualize cellular 




Itraconazole binds directly to NPC1 
 
Niemann-Pick type C disease results from mutations in one of two lysosomal 
proteins, NPC1 and NPC2, with predicted molecular weights of 142 and 16.5 kDa, 
respectively. Although we did not observe any proteins of these molecular weights in the 
whole cell photolabeling experiment, we decided to specifically test whether the 
itraconazole photoaffinity probe could bind to either or both of these proteins by 
expressing tagged versions of the proteins in 293T cells and performing Western blots to 
detect the tag after the photocrosslinking and biotin pull-down. Surprisingly, myc-tagged 
NPC1 was pulled down by the probe, and was also competed away by excess 
itraconazole (Figure 3.5), suggesting that itraconazole is able to bind NPC1 directly. 
Myc-tagged NPC2, on the other hand, did not show any labeling by the probe. 
Endogenous NPC1, but not NPC2, could also be pulled down from 293T cells (Figure 
3.6a,b), although the expression of NPC1 protein appeared to be fairly low in these cells. 
After testing NPC1 expression in several cell lines we found that A549 expressed higher 
levels of NPC1 (Figure 3.6c), and upon repeating the photolabeling experiment in A549 
















Figure 3.5: Photolabeling of exogenously expressed, myc-tagged NPC1 and NPC2. 
The photoaffinity labeling and biotin pull-down was performed in 293T cells co-
transfected with plasmids expressing myc-tagged NPC1 and NPC2. Tagged NPC1 is 
clearly pulled down by the probe and competed away by itraconazole, whereas no NPC2 
















Figure 3.6: Photolabeling of endogenous NPC1 and NPC2. A) Labeling of 
endogenous NPC1 was detectable in 293T cells. B) No labeling of endogenous NPC2 
was detectable in 293T cells. C) A549 cells were found to express the highest levels of 
NPC1 out of several cell lines tested. D) Labeling of endogenous NPC1 was clearly 
detectable in A549 cells.   
	 139	
NPC1 is an integral membrane protein with a 13-pass transmembrane C-terminal 
domain and a soluble N-terminal domain (NTD) that faces into the lumen of the 
lysosome and interacts directly with NPC2 to transfer cholesterol between the two 
proteins. To determine whether itraconazole binds to the integral membrane or soluble 
portion of the protein, we expressed the NTD alone (aa 1-264) with a FLAG tag and 
repeated the photocrosslinking and pull-down experiment. There was no observable 
photocrosslinking to the NTD as compared with the full-length protein (Figure 3.7), 











Figure 3.7: Photolabeling of expressed tagged NPC1 and NPC1(NTD). 293T cells 
were transfected with either A) myc-tagged NPC1 or B) FLAG-tagged NPC1(NTD) 
before photolabeling and biotin pull-down. Only the full-length protein could be pulled 
down by the probe.   
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Several small molecules that induce NPC phenotype have been identified and 
used as tool compounds to study the cholesterol trafficking defect found in patients with 
NPC disease. One of these is the sterol analog U18666A, which was recently shown to 
bind directly to the sterol-sensing domain of NPC115. Another drug, indatraline, was also 
found to induce NPC phenotype through an unknown mechanism (Figure 3.8). To 
determine if these drugs were able to bind to NPC1 at the same site as itraconazole, we 
tested whether they could compete the binding of the itraconazole probe to NPC1. We 
also tested triazole-deleted itraconazole (TD-itra) and terconazole, another azole 
antifungal drug, as both had been shown to induce NPC phenotype. Thus, cells were pre-
incubated with 10 µM of itraconazole or 20 µM of the other competitors for 30 min, 
before adding the itraconazole probe and performing the photoaffinity labeling 
experiment followed by biotin pull-down and Western blot for NPC1 (Figure 3.9a). As 
before, itraconazole clearly competed away binding of the itraconazole probe, while the 
other 4 competitors all appeared to partially compete with the binding (Figure 3.9b). 
This experiment suggested that these other NPC-inducing compounds might also bind 
















Figure 3.8: Indatraline induces NPC phenotype in HUVEC. HUVEC were treated 
with the indicated concentrations of itraconazole or indatraline (inda) for 24 hours and 
cholesterol distribution was observed by filipin staining.  
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Figure 3.9: Photolabeling of NPC1 is partially competed by other NPC-inducing 
compounds. A) Photolabeling in A549 cells using itraconazole (ita), indatraline (ind), 
triazole-deleted itra (TD), U18666A (U18), or terconazole (ter) as competitors 
(itraconazole was used at 10 µM, all other compounds at 20 µM). B) Quantification of the 
western blot shown in figure A by densitometry shows that the NPC1 signal in the 
itraconazole competition sample is about 15% of the probe sample, while the other 4 
competitor molecules have about 40-50% signal remaining.   
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AMPK activation and NPC induction lead to synergistic inhibition of mTOR 
 
The fact that itraconazole binds directly to both VDAC1 and NPC1 suggested that 
AMPK activation and NPC phenotype induction might be two unrelated effects of 
itraconazole that both result in mTOR inhibition by different mechanisms. Inhibitors of 
cholesterol trafficking (U18666A, imipramine) and activators of AMPK (2DG, aspirin) 
were both previously shown to inhibit mTOR individually. We therefore wondered if 
simultaneously targeting these two upstream pathways would lead to a synergistic effect 
on mTOR. Synergy, or superadditivity, is observed when the effect of the combination of 
two or more compounds is greater than the sum of the effects of those compounds 
individually. Thus, if the sum of the individual effects of AMPK activation and NPC 
induction on mTOR were less than the effect of simultaneous AMPK activation and NPC 
induction on mTOR, then the effect would be considered synergistic. Accordingly, 
HUVEC were treated with the NPC inducer U18666A, as well as a direct AMPK 
activator called A769662 (the direct AMPK activator was used instead of 2DG or aspirin 
to avoid confounding effects on other cellular processes). A range of concentrations of 
each drug was chosen that had little or no effect on mTOR when given to cells 
individually (3-30 µM U18, 10-100 µM A76). However, when an intermediate 
concentration of each drug was combined with the other, there was a clear intensification 
of the effect on mTOR (Figure 3.10). For example, 10 µM U18 did not show obvious 
inhibition of mTOR on its own, but when combined with A76 the effect of A76 was 
significantly increased at all concentrations tested. Likewise, 30 µM A76 alone did not 
have an obvious effect on mTOR, but when combined with U18 it significantly enhanced 
the inhibition of mTOR by U18. These preliminary results support the hypothesis that the 
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combination of cholesterol trafficking inhibitors and AMPK activators can synergistically 
inhibit mTOR. Thus, by binding directly to both VDAC1 and NPC1, itraconazole 
simultaneously targets both pathways to produce a stronger effect on mTOR than an 
individual inhibitor of either protein would be able to. To our knowledge, this makes 













Figure 3.10: Combination treatment of HUVEC with the NPC inducer U18666a and 
the AMPK activator A769662. At 30 µM, A769662 does not significantly inhibit 
mTOR on its own (lane 4), but it does enhance the inhibition of mTOR by U18666A 
(lanes 9-14). Likewise, 10 µM U18666A does not inhibit mTOR in its own (lane 7), but 










NPC1 inhibition prevents the trafficking of cholesterol from the late endosomal-
lysosomal compartment, leading to its accumulation in this compartment and its depletion 
from other cellular membranes. The observation that itraconazole induced this so-called 
NPC phenotype in HUVEC led to the connection being made between cholesterol 
trafficking and mTOR inhibition in endothelial cells6. However, the direct target of 
itraconazole that mediated this NPC phenotype induction was not known. In this chapter, 
we demonstrate that the antifungal drug itraconazole binds directly to NPC1 using a 
photoaffinity labeling approach in live cells.  
Previous work had shown that the inhibition of mTOR and HUVEC proliferation 
by itraconazole could be partially rescued by adding back cholesterol in complex with the 
carrier molecule β-cyclodextrin. This result suggested that these effects of itraconazole 
might be mediated by a target whose activity is sensitive to cellular cholesterol levels. 
NPC1 contains a sterol-sensing domain (SSD) that has been shown to be critical for its 
ability to sense cholesterol in the membrane and promote its egress from the lysosome10. 
Recently, the NPC inducing compound U18666A was shown to bind directly to NPC1, 
and this binding was mapped to residues in the SSD by a point mutation within this 
domain (P691S) that prevented U18 binding. The fact that the itraconazole probe was 
unable to crosslink to the NTD alone and that photoaffinity labeling of NPC1 by the 
itraconazole probe is partially competed by U18 (Figure 3.9a) suggests that 
itraconazole’s binding site on NPC1 may be located in the transmembrane portion of the 
protein, possibly that same SSD site to which U18 binds.  
The minimal structural determinants for binding of itraconazole to NPC1 are not 
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clear. From the competition experiment in figure 3.9, it appears that neither the azole 
ring nor a large portion of the distal structure (phenyl-triazolone-isobutyl chain) are 
required for binding NPC1, as both TD-itra and terconazole are able to partially compete 
the binding of the itraconazole probe. The fact that U18666A and indatraline are also able 
to partially compete this binding suggests that the itraconazole binding pocket on NPC1 
may be relatively non-specific. Indeed, in the recent report of U18666A binding to NPC1, 
it was suggested that the binding site “may lack the exquisite sensitivity of the 
[cholesterol binding site in the] NTD, and it may bind U18666A and other cationic 
amphiphiles that thereby block cholesterol egress from lysosomes”15. This hypothesis is 
also supported by the fact that every itraconazole analog synthesized and tested by our 
lab to date is able to induce NPC phenotype (data not shown). However, further work 
will determine whether any analogs diverge in their ability to activate AMPK and inhibit 
cholesterol trafficking, which would give interesting insights into the differences of the 
binding sites on NPC1 and VDAC1. In addition, if itraconazole does bind to the SSD of 
NPC1, it would be important to determine whether it also binds to other members of the 
SSD-containing family of proteins, which include the cholesterol biosynthetic enzymes 
HMG-CoA-reductase (HMGCR) and 7-dehydrocholesterol reductase (7DHCR), the 
SREBP-cleavage activating protein (SCAP), and the Hedgehog receptor patched.  
The concept of polypharmacology, or a drug acting on more than one target, is not 
a new idea but has been recently gaining a renewed appreciation18. Until recently, most 
people considered so-called “dirty drugs” to be undesirable, as a high specificity and 
potency for a single target would presumably have powerful activity against the target 
with minimal side effects. However, this idea of a “magic bullet” to cure disease has not 
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been borne out clinically; in many situations, cells can compensate for inhibition of a 
single target either by developing resistance mutations or otherwise decreasing their 
dependence on that target. In cancer treatment in particular, due to an increased rate of 
genetic mutation, treatment with single targeted drugs often leads to selection of drug-
resistant mutants. The same can be said for antimicrobial and antiviral drugs, due to the 
rapid proliferation rate and difficulty in achieving 100% eradication of the 
microorganism. Therefore, there is an increasing appreciation that simultaneous 
inhibition of multiple targets may lead to a decreased incidence of drug resistance, as the 
probability of a cell mutating or compensating for the loss of two targets at the same time 
is greatly reduced. One strategy to accomplish this is to use one or more single-targeted 
drugs in combination, such as with the cocktail of drugs used to treat HIV known as 
highly active antiretroviral therapy (HAART). However, this approach has the 
disadvantage of compounding side effects and the possibility of drug-drug interactions 
due to drug metabolism or other factors. In addition, individual pharmacokinetic 
differences between patients can make the dosing of multiple drugs at once even more 
challenging for physicians. Alternatively, using one drug with multiple targets can 
accomplish the same goal of combating resistance mechanisms while avoiding problems 
of drug-drug interactions, complicated dosing schedules, and increased side effects. To 
design a drug for the specific purpose of targeting multiple proteins simultaneously is 
more challenging, but can be accomplished through counterscreening. For example, 
receptor tyrosine kinases (such as EGFR or HER2) are a common target in cancer 
treatment, but their inhibition by small molecules can induce resistance mechanisms 
involving upregulation of PI3K activity. By screening a library of tyrosine kinase 
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inhibitors for PI3K activity, the kinase inhibitor PP121 was found that inhibits both 
targets, thus preventing this mechanism of resistance from occurring18.  
 A related concept in drug combinations and polypharmacology is the concept of 
synergy. By definition, synergy is when the combination of two or more compounds 
produces an effect that is greater than the sum of its individual parts. In pharmacology, 
drugs that target multiple upstream inputs to a single cellular process are often found to 
be synergistic in combination. Similarly, it is possible for a single drug to induce an 
apparent synergistic effect by simultaneous targeting of multiple pathways. Although 
quantifying the synergy of a single drug is challenging without finding a way to measure 
its effects on one individual target at a time, we can use other specific inhibitors of each 
pathway to provide proof-of-concept for the synergistic inhibition of a downstream 
effect. Thus, in a preliminary experiment, we approximated the inhibition of the two 
targets of itraconazole (NPC1 and VDAC1) by combining the NPC1 inhibitor U18666A 
and the direct AMPK activator A769662 and measuring the effects on mTOR. By 
Western blotting for phosphorylation of the mTOR substrate S6K, we clearly observed a 
greater effect on mTOR activity by the combination of the two compounds than by each 
compound individually. In follow-up studies, we plan to further confirm the synergistic 
effect of other AMPK activators (including the VDAC inhibitor erastin) and NPC 
inducers on mTOR and HUVEC proliferation by using a larger number of drug doses and 
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Chapter 4: Perspectives and Future Directions 
	
	
Target identification is a challenging but critical step in the phenotypic drug 
discovery process. Many different methods have been developed for this purpose and 
each has advantages and disadvantages (as summarized in Chapter 1). Generally, 
however, it is not possible to know beforehand which approach will be successful for a 
given molecule, particularly without prior information about the type of target. Certain 
characteristics of the small molecule may be helpful in determining which methods are 
more likely to succeed; for example, water soluble drugs are generally more likely to 
bind to soluble proteins, for which affinity purification from cellular lysates may be 
appropriate, while lipid soluble drugs may be more likely to bind to membrane proteins, 
in which case a native approach that does not require cell lysis may be more effective. 
Molecules containing a reactive group such as epoxide, fluorophosphonate, or β-lactam 
are more likely to bind their target covalently1, while those with bulky hydrophobic 
structures may interact non-covalently with their target, for which a crosslinking strategy 
may be preferable2. Many molecules interact with a specific binding pocket of a protein 
receptor, but others exert their effects through binding to DNA, RNA, lipids or 
carbohydrates, or otherwise non-specifically affect cellular function by mechanisms such 
as aggregation or alteration of organellar pH, in which case a target ID method with a 
protein-only readout will never be successful. Certain structural features have been 
observed in the types of molecules that act in these ways3–7; however, there are 
exceptions to every rule and it cannot be predicted with absolute certainty that a given 
strategy will be effective in identifying the target of a particular molecule. It is therefore 
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critical to be aware of the inherent biases and pitfalls of each method, and whenever 
possible combine the use of multiple techniques with minimal overlap in their particular 
weaknesses.  
The antifungal drug itraconazole was identified in a high-throughput screen of 
clinically used drugs for its ability to selectively inhibit endothelial cell proliferation. 
Through a top-down, or phenotype-based approach, it was subsequently found to inhibit 
the mTOR signaling pathway, cholesterol trafficking, and VEGFR2 glycosylation in 
HUVEC. Each of these processes have been studied extensively by other researchers and 
many key molecular players identified, and as such a significant amount of luck would 
have been required to find the relevant target of itraconazole by testing each one 
individually. Thus, we sought to identify the molecular target(s) directly using a “bottom-
up”, or unbiased chemical approach. Initially, a biotinylated version of itraconazole was 
synthesized and used in affinity pull-down experiments with cellular lysates, but no 
obvious binding proteins were observed by silver staining. In retrospect, given the poor 
aqueous solubility of itraconazole and the lack of any reactive groups that might indicate 
covalent binding, we might have predicted that the biotin pull-down strategy was unlikely 
to succeed for this molecule. Therefore, a photoaffinity labeling approach was employed 
to allow binding and covalent modification of the target to occur in a native cellular 
environment. The proteins pulled down and identified by MS were all membrane proteins 
(mEH, CPT2, VDAC1, NPC1), suggesting that itraconazole probably does partition into 
cellular membranes. However, the fact that the photoaffinity probe did not pull down 
Tom40, another integral membrane protein, demonstrated that the probe did not non-
specifically label all membrane proteins.  
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A major challenge with target identification, once one or more binding proteins 
are identified, is validation of the relevance of these proteins to the observed bioactivity 
of the small molecule. If only one binding protein is identified and its known function 
completely explains the observed phenotype, then validation will be straightforward. In 
the case of itraconazole, 3 major binding proteins were identified by the whole cell 
labeling experiment, none of which had been previously implicated in any of the 
observed effects of itraconazole in HUVEC. Additionally, a 4th binding protein, NPC1, 
was not detected using this “unbiased” method, possibly due to its low cellular abundance 
in comparison with the other binding proteins. Determining the relevance of any of these 
proteins to a drug phenotype then becomes challenging, particularly if the true effect of 
the drug involves activity against more than one protein at once. The discovery that 
itraconazole activated AMPK and this activity was mediated by VDAC1 was 
serendipitous, and still did not explain the full phenotype of the drug, which also involves 
inhibition of cholesterol trafficking by NPC1. We also cannot rule out the possibility that 
CPT2, mEH, or other unidentified targets may contribute to its effects.  
To summarize, photoaffinity labeling can be a powerful tool for small molecule 
target identification in many situations. Its main advantages are that 1) ligand-target 
interaction occurs in the native environment of a living cell, making it highly useful for 
insoluble membrane proteins; 2) the binding partners are covalently attached by 
photocrosslinking, ensuring the interaction will be preserved after cell lysis and 
subsequent manipulation steps; 3) the specificity of the probe binding is measured 
directly by competition with the parent compound (or any other molecule that you want 
to know if it binds to the same site); and 4) the identification of targets is “unbiased” in 
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that all cellular proteins are present and available for labeling and identification, or 
alternatively, binding to specific targets can be tested by pull-down/Western blot without 
necessitating protein purification and binding assays for each one. Its disadvantages are 
that 1) it is more likely to detect more abundant cellular targets; 2) it requires that the 
target of the small molecule be a protein; and 3) it requires subsequent validation of the 
target’s biological relevance through further functional experiments. Thus, as with all 
scientific techniques, it is best to use this photoaffinity labeling approach in combination 
with other techniques such as a top-down approach or genetic methods.  
In this work, we used photoaffinity labeling to identify VDAC1 as a novel target 
of itraconazole, and employed genetic (knockdown/knockout) and various cell-based 
assays to validate that VDAC1 is relevant to the observed phenotype of itraconazole in 
endothelial cells. In the process, we also uncovered a new activity of itraconazole, the 
activation of the AMPK signaling pathway. A large number of AMPK activating small 
molecules have been discovered and used clinically or scientifically, including the 
clinical drugs metformin, phenformin, aspirin, and the thiazolinediones; the metabolite 
analogs 2DG and AICAR; synthetic direct AMPK activators A769662 and PT1; and 
natural products such as resveratrol and other polyphenols, berberine, and curcumin8,9. 
However, the concentrations of these drugs required to activate AMPK are generally very 
high (>1 mM for aspirin, 2DG, and AICAR; high µM range for metformin), and even for 
the synthetic direct AMPK activator A769662, concentrations in excess of 50 µM are 
required to activate AMPK in our experiments. Itraconazole, on the other hand, can 
induce detectable AMPK activation in HUVEC at concentrations as low as 300 nM, 
which to our knowledge makes it the most potent AMPK activator reported to date. 
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The discovery that itraconazole potently activates AMPK suggests new potential 
therapeutic applications of the drug in addition to its antifungal and antiangiogenic use. 
AMPK activators are most commonly used clinically as antidiabetic drugs, due to their 
ability to suppress hepatic glucose production. Although itraconazole has been shown to 
have hepatotoxicity in some patients at high doses during treatment for fungal infections, 
lower doses are generally very well tolerated in patients and might be sufficient to 
activate AMPK in the liver without inducing toxicity. In addition, the pure stereoisomer 
IT-C (2S,4R,2’S) was shown to have significantly lower hepatotoxicity with increased 
antiangiogenic activity10. If this isomer also induces AMPK with the same or greater 
potency than the mixture of cis-isomers, it would be worth investigating for this purpose, 
either alone or in combination with currently used diabetic drugs.  
In addition to diabetes, AMPK has also been shown to be a potential target in 
acute lymphoblastic leukemia (ALL) and B-cell chronic lymphocytic leukemia (B-
CLL)11,12. Interestingly, one study that investigated itraconazole in ALL and AML 
patients showed an increase in disease-free survival of ALL patients who were given 
itraconazole, which the authors suggested might be attributable to reversal of multidrug 
resistance through inhibition of p-glycoprotein13. We are currently testing itraconazole in 
several ALL cell lines to determine its effect on AMPK and proliferation, which may 
lead to a rationale for clinical trials to be expanded from the cancer types already being 
investigated. However, at a minimum, it could be argued that ALL patients who are 
already being given azole drugs for antifungal prophylaxis could potentially benefit more 
from itraconazole than the other azoles, which do not activate AMPK.  
The identification of NPC1 as a target of itraconazole also opens up the 
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possibility for new potential therapeutic uses. In particular, NPC inducers have been 
shown to have activity against certain viruses, including Ebola, Marburg, Filovirus and 
HIV14–18. Itraconazole and U18666A were recently shown to have activity against 
enterovirus and hepatitis C replication, thought to be mediated by inhibition of oxysterol-
binding protein (OSBP)19. U18666A was also shown in another study to inhibit dengue 
virus entry and replication20. It would be highly worthwhile to test itraconazole against a 
panel of different viruses to see if it has activity, as it is not only significantly more potent 
than U18 at inducing NPC phenotype but is also an FDA-approved drug that could be 
rapidly repurposed for short-term antiviral use.  
Another intensive effort by our lab over the past several years has been the 
synthesis of structural analogs of itraconazole, and to date we have made over 75 such 
analogs21–23. Ongoing efforts to characterize the activity of these analogs against each of 
itraconazole’s effects – mTOR inhibition, NPC phenotype, Hedgehog, proliferation – has 
revealed analogs with improved activity, better water solubility, and less cross-inhibition 
of drug metabolizing enzymes. Further studies will investigate whether any of these 
analogs might be more selective inhibitors of either VDAC1 or NPC1, which could 
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Awards and academic activities 
• Awarded Predoctoral Fellowship in Pharmacology/Toxicology from the PhRMA 
Foundation in 2014  
• Profiled two Pharmacology faculty members for JHM Science News newsletter, 
2015. 
• Student Research Mentor (2012, 2013, 2014, 2015). 
• Graduated cum laude; Dean’s list Fall 2006, Fall 2007, Fall 2008, Spring 2009. 
Invited seminars and poster presentations 
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